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This dissertation will examine the use of novel affinity sorbents to extract
emerging contaminants from water. These contaminants include carbamazepine, an antiepileptic drug which is resistant to natural degradation in the environmental and to
drinking water treatment procedures. This drug has been found in fish, drinking water,
estuarine and coastal waters, and river sediment and has been used as a general marker of
contaminants in wastewater. Carbamazepine was one of the most commonly detected
compounds in surface-water and groundwater samples in a recent reconnaissance study
of untreated drinking water sources in the U.S. Besides using this drug as a
representative contaminant for testing albumin-based extraction methods, other sections
of this dissertation will include a discussion of the combination of on-line
immunoextraction using anti-carbamazepine antibodies with RPLC/MS. Research will
be presented involving the use of this method with molecularly imprinted polymers
(MIPs) to extract emerging contaminants from water.
Other studies in this dissertation will include the use of serum protein columns to
not only retain drugs but to provide chiral separations. This approach will be used to
examine the retention of some chiral drugs by the serum protein α1-acid glycoprotein.
Another part of this dissertation will include a discussion of how chromatographic theory

can be used to describe the binding and extraction behavior of albumin columns when
used to retain emerging contaminants. In addition, it will be shown how the same types
of protein columns can be used to examine the kinetics of drug-protein interactions.
Possible future directions for this work will also be discussed.
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CHAPTER 1
GENERAL INTRODUCTION

BIOLOGICALLY-ACTIVE ENVIRONMENTAL CONTAMINANTS
Over the last decade there has been increasing research in the area of biologicallyactive “emerging contaminants”. These environmental pollutants are organic compounds
that have both industrial and agricultural sources and include substances whose
environmental effects are not fully understood and for which regulations are not yet in
place.1 These contaminants are typically present in trace amounts and are of concern in
surface water, soil, sediment and groundwater. Included in this class of compounds are
human and veterinary pharmaceuticals and their metabolites, personal care products,
natural and synthetic hormones, endocrine disrupting compounds, disinfection
byproducts, flame retardants, surfactants, plasticizers, pesticide degradation products and
new pesticides, as well as sucralose, antimony, nanomaterials, antibiotic resistance genes
and prion proteins.2-4
There are many pathways that biologically active contaminants can follow when
entering the environment. Some examples include pesticide application, manure
application, feedlot runoff, wastewater treatment plant effluent, land application of
treated municipal wastewater and biosolids, stormwater runoff, leaching into
groundwater, uptake into food crops, discharge of wastewater into water bodies, sewer
overflows, septic tank effluent, industrial waste discharge, release into surface waters of

antibacterials used in aquaculture, and improper disposal of unused medicines.3, 5,6, 7
Figure 1-1 shows some examples of pathways for veterinary medicines. Knowing the
sources and pathways of contaminants is not only helpful in reducing the input of these
compounds into the environment but also aids in assessing the risk they pose to human
health and to the ecosystem.6
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Figure 1-1.

Pathways for the entry of biologically-active contaminants into the
environment (Reproduced with permission from Ref. 5).
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There have been many studies of the occurrence of biologically-active
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contaminants in various settings. These contaminants have been found in plants and
animals, including human tissue.8 These contaminants have also been detected in waters
throughout the world,6, 9 including sources of public drinking water.8 It is difficult to set
drinking water standards because information on the large-scale occurrence of
biologically-active contaminants is only beginning to become available and there are few
standardized methods for analyzing these agents.8 There is also evidence that drought
caused by climate change can lead to increased concentrations of pharmaceuticals and
endocrine-disrupting compounds in surface water and drinking water sources.10
Population growth and urbanization have led to the use of treated, partially treated and
even untreated wastewater for agricultural irrigation in many parts of the world. There is
the potential for pharmaceuticals in such water to be leached into groundwater.3
These contaminants are of concern because their fate in the environment and
therefore, their potential impact on the environment and on human health are not well
known.3, 11, 12 However, many of these contaminants are suspected of causing diseases or
developmental abnormalities in wildlife and humans and some confirmed to do so .3, 13
Biologically-active contaminants can also interact with each other in the environment.6
For example, the degradation of naproxen has been shown to be diminished by the
presence of antibiotics in soil.14 Sorption of these compounds by soil creates the
potential for extensive and long-term water contamination. Soil also acts as a reaction
catalyst for some contaminants.3
Personal care products are the source of the antibacterial compounds triclosan and
triclocarban, which are added to soaps, deodorants, skin creams, mouthwashes,

toothpastes, cosmetics, fabrics and plastics.15,16 Triclosan and triclocarban easily pass

6

through wastewater treatment systems because they are hydrophobic and may end up in
the environment through biosolids application to agricultural fields, which is an
increasingly common practice in the United States.3 Not much is known about the fate of
these compounds after they enter the soil.17 The concern about triclosan is that it may be
an endocrine disruptor18 and cause resistance to antibiotics in bacteria.19 Although
triclocarban is not an endocrine disruptor on its own, it is thought to enhance testosterone
action.20
Other biologically-active compounds (e.g., pharmaceuticals, hormones and
endocrine disrupting compounds) are also difficult to remove completely during
wastewater treatment. The concern over the environmental release of pharmaceuticals
such as antibiotics is their contribution to the development of antibiotic-resistant bacteria
as well as the reduced biodegradation of plant material. This latter issue is a concern
because plants are an important source of food for aquatic organisms. Natural hormones
and synthetic chemicals that mimic hormones have possible estrogenic effects and other
effects on animals and humans. For example, the contraceptive α-ethinylestradiol (EE2)
affects sexual characteristics and decreases egg fertilization in fish at low and
subnanogram per liter levels.21

ANALYSIS OF ENVIROMENTAL CONTAMINANTS
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Detection levels for manufactured and natural organic compounds are often in the
sub-parts per billion to sub-parts per trillion levels.8 Liquid chromatography-mass
spectrometry (LC/MS) and liquid chromatography-tandem mass spectrometry
(LC/MS/MS) are commonly used for the analysis of these and other compounds in
environmental samples.8, 9, 21, 22 These techniques combine compound-specific fragments
that are produced by the mass spectrometer with the use of chromatographic retention to
clearly separate and identify compounds. Another advantage of using mass spectrometry
as part of these methods is the ability of this approach to consult data files even months
after an analysis for the identification of unknown compounds.21 In order to overcome
matrix effects and ion suppression in wastewater samples, isotopically labeled standards
are often used in these measurement methods. These internal standards are usually
deuterated or contain 13C and are often quite costly.2, 23 More efficient and selective
extraction or pretreatment methods for the desired analytes can be useful in these
situations.
In order to provide relevant detection limits for trace analysis in environmental
samples, extraction and preconcentration are typically required prior to sample
introduction to an HPLC system. Solid-phase extraction (SPE) is the most common
method of extraction and concentration for environmental samples; in some instances,
online SPE has even been used.21, 24 To provide more efficient and selective methods of
extraction, affinity based sorbents have been used in some research for the analysis of
pesticides.25-27 Affinity ligands are usually of biological origin and include antibodies,
enzymes, serum proteins, lectins, carbohydrates and avidin/streptavidin. These binding

agents, or “affinity ligands”, make use of selective interactions of many biological
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systems to efficiently extract sample components for analysis or purification. These
ligands may be immobilized to high-performance chromatographic supports to give a
technique known as high-performance affinity chromatography (HPAC); this method is
also known more specifically as high-performance immunoaffinity chromatography
(HPIAC) when antibodies are used as the ligands.28, 29
An example of this latter type of work is a previous study in which HPIAC was
coupled to reversed-phase liquid chromatography (RPLC) to analyze atrazine and its
major degradation products in water.25 The compounds of interest in this particular
example were extracted by the anti-atrazine monoclonal antibodies immobilized to silica
in the immunoaffinity column and then separated using an on-line reversed-phase
column. Compared to the reference methods of gas chromatography-mass spectrometry
(GC/MS) and gas chromatography with nitrogen-phosphorus detection (GC/NPD), the
HPIAC/RPLC method had similar accuracy and precision. However, since there was no
need for extraction or sample derivatization before analysis, the HPIAC/RPLC method
was quicker, less labor intensive and required smaller amounts of solvents.25 It was also
possible to use this system to measure atrazine degradation products at environmentally
significant concentrations in the parts-per-trillion range (i.e., nanograms per liter
concentrations).26 A similar, portable immunoextraction/RPLC system was developed to
analyze atrazine and other triazine herbicides in groundwater and surface water.27 In
another example of immunoextraction, monoclonal antibodies to 17β-estradiol and
estrone were used to selectively extract these steroid estrogens from wastewater samples.

The extracts were then analyzed using HPLC-electrospray MS with a C18 column for
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separation.30

ALTERNATIVE ANALYSIS STRATEGIES FOR EMERGING CONTAMINANTS
Another, less expensive option to antibodies that will be explored in this
dissertation is the use of serum transport proteins as the basis for affinity sorbents for
steroid hormones, drugs and other emerging contaminants. Like antibodies, proteins such
as human serum albumin (HSA) and bovine serum albumin (BSA) have relatively high
selectivity and strong binding for their target compounds.29, 31 Albumin is the most
abundant plasma protein in vertebrates. HSA has a molecular weight of 66.5 kDa, and
has a single polypeptide chain that contains 585 amino acids. HSA also contains 17
disulfide bridges, which stabilize its structure by folding and looping together α-helices.
BSA has a similar mass and structure to HSA but contains only 583 amino acids.29
Albumin is produced by the liver and performs a variety of functions in the body.
These functions include the ability of albumin to bind and deliver organic anions, longchain fatty acids, drugs, vitamins and other substances through the blood stream. Other
functions of albumin involve its role in regulating osmotic pressure, protecting lowdensity lipoproteins from peroxidative effects, and acting as a buffering system for
extravascular fluids.29 Chapter 5 will present the development of affinity sorbents for
use of albumins in the on-line extraction of biologically-active environmental
contaminants in water analysis using LC/MS/MS.

One compound that will be used to test this approach is carbamazepine.
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Carbamazepine is an anti-epileptic drug which is resistant to natural degradation in the
environment and to drinking water treatment procedures.32-34 This drug has been found
in fish, drinking water, estuarine and coastal waters, river sediments21, 35, 36 and has been
used as a general marker of contaminants in wastewater.37 Carbamazepine was one of
the most commonly detected compounds in surface-water and groundwater samples in a
recent reconnaissance study of untreated drinking water sources in the U.S.8 Also, the
chronic toxicity lowest observed effect concentration (LOEC) of carbamazepine is close
to its levels that are observed in wastewater effluents.21 Chapter 5 will illustrate using
this drug as a representative contaminant for testing albumin-based extraction methods,
and Chapter 2 will include discussion of the combination of on-line immunoextraction
using anti-carbamazepine antibodies with RPLC/MS. In Chapter 3 research will be
presented involving the use of this method with molecularly imprinted polymers (MIPs)
to extract emerging contaminants from water.
Another sampling and concentration option for environmental contaminants that
will be considered in this dissertation is the use of a polar organic chemical integrative
sampler (POCIS) extraction membrane. This method has been shown to be useful when
it is not feasible, convenient or helpful to collect grab samples. Under some conditions,
POCIS provides a time-weighted average concentration of the compound of interest. It
also has the advantage of being equivalent to the respiratory exposure of aquatic
organisms38.
Other studies in this dissertation will include the use of serum protein columns to
not only retain drugs but to provide chiral separations. This approach will be used in

11

Chapter 4 to examine the retention of some chiral drugs by the serum protein α1-acid

glycoprotein. Chapter 5 will include a discussion of how chromatographic theory can be
used to describe the binding and extraction behavior of albumin columns when used to
retain emerging contaminants. In addition, Chapter 6 will show how the same types of
protein columns can be used to examine the kinetics of drug-protein interactions.
Chapter 7 will summarize the results of this dissertation and discuss some possibilities for
future studies.
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HIGH-PERFORMANCE IMMUNOSORBENTS FOR THE SELECTIVE TRACE
ANALYSIS OF EMERGING CONTAMINANTS IN WATER
Note: The following is adapted from High-Performance Immunosorbents for the
Selective Trace Analysis of Emerging Contaminants in Water, D. S. Hage, E.
Papastavros, D. D. Snow, Proceedings WEFTEC, 2010.

INTRODUCTION
A wide variety of polar organic chemicals such as pharmaceuticals, steroids, and
personal care products are released into the environment through municipal wastewater
and the application of biosolids. Studies of surface and ground water quality are now
considering the impact of these difficult-to-analyze contaminants on aquatic organisms
and human health. Low concentration chemicals such as X-ray contrast agents, steroids,
antibiotics and other pharmaceuticals have been detected in water bodies impacted by
wastewater.1-5Because of their persistence, a few refractory organics, ranging from health
care products and human steroid hormones to caffeine and its metabolites and even
artificial sweeteners, are now considered potential wastewater markers in surface and
ground water systems.
Exceedingly low, parts-per-trillion, levels of these individual chemicals in water
may not in itself raise serious health concerns. However, the persistence and occurrence
of these chemicals in water supplies may have implications for both human water-borne
diseases and risks to environmental health.3, 6-9 Since drinking water treatment

technologies do not typically remove these contaminants, some may even be found in
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treated water supplies.10 Many questions remain as to the relative importance of different
sources of these agents and the environmental factors that control the occurrence and fate
of these chemicals. Because of these concerns and uncertainty, there is an increasing
need to assess the sources, occurrence and effects of these biologically-active
environmental contaminants in water. Many of these chemicals are water soluble,
making their separation more challenging. They are typically found in very complex
matrices, such as bio-solids or sludge, sediments, manures, and waste-impacted natural
waters, further adding to the difficulty of analysis. These factors have created a pressing
need for improved sampling and detection technologies for these micro-constituents.
Highly efficient extraction and purification methods are needed to extract these
compounds from complex matrices and to separate them from interferences, i.e. species
other than the analyte of interest that can affect the response of the analytical method. .
Existing methods for such work typically use either bonded silica or polymeric sorbents
for concentrating contaminants from water. Although recoveries can be quite good using
these nonselective sorbents, large quantities of potential interferences are often coextracted leading to reduction in the sensitivity and accuracy of the analysis.
Immunosorbents (i.e., supports containing immobilized antibodies as selective binding
agents) show great promise as an alternative approach for this type of work.11, 12
Immunosorbents have previously been employed for both off- and on-line extraction with
LC and LC/MS, as well as in the automation of immunoassays.13 Advantages of using
immunosorbents for the extraction and detection of micro-contaminants such as steroids
include their high selectivity and strong binding for a target, as illustrated in recent work

performed with such supports in the liquid chromatography-tandem mass spectrometry
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analysis of estrogens (17β-estradiol and estrone) in raw sewage samples.14
Immunosorbents and related sorbent technologies are only beginning to see applications
in environmental analysis.15 These materials provide a high degree of selectivity and
retention needed for concentrating polar organic contaminants such as pharmaceuticals
form large volumes of water.16
Development of a selective sorbent first requires identification of a contaminant
or contaminant class to be concentrated and separated from water. Though many
organics have been reported in wastewater effluent and in water impacted by wastewater,
a few are frequently observed, probably reflecting both widespread use and resistance to
biological degradation.
For example, traces of the anti-seizure medications primidone and
carbamazepine, as well as the stimulant caffeine, were detected downstream from
wastewater treatment plants in California, Pennsylvania, Colorado, Oklahoma and New
Jersey.17 In another study,18 researchers detected traces of carbamazepine in groundwater
near a municipal wastewater treatment lagoon by Tel Aviv, Israel. A recent national
reconnaissance by the U.S. Geological Survey found traces of 63 organic contaminants in
untreated drinking water supplies across the U.S.6 The five most frequently detected of
the targeted chemicals in surface water used as a drinking water source included
cholesterol, metolachlor (a herbicide), cotinine (a nicotine metabolite), β-sitosterol (a
plant sterol), and 1,7-dimethylxanthine (a caffeine metabolite). The same study also
investigated ground water supplies, finding traces of carbamazepine along with
tetrachloroethylene (a chlorinated solvent), bisphenol-A (a plasticizer), 1,7-

dimethylxanthine and tri(2-chloroethyl) phosphate (a flame retardant). Based on these
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and other reports, carbamazepine frequently appears in municipal wastewater19 and is
resistant to biodegradation with little removal during wastewater treatment.20
The objective of this chapter is to illustrate the use of immunosorbents for
development of an improved method for concentration and detection of pharmaceuticals
such as carbamazepine in order to help understand and measure impacts of wastewater on
water quality. Other contaminants reported here to illustrate the use and selectivity of
immunosorbents are triazine herbicides, such as atrazine, and chlorophenoxyacetic acid
herbicides, such as 2,4-D. Atrazine is particularly ubiquitous in the environment and has
been detected at low levels in drinking water supplies from across the U.S. In a recent
study of pharmaceuticals and endocrine disruptors in U.S. drinking water5, the most
frequently detected compounds included atenolol, atrazine, carbamazepine, estrone,
gemfibrozil, meprobamate, naproxen, phenytoin, sulfamethoxazole, TCEP, and
trimethoprim. Atrazine, together with its degradation products deethyl- and
deisopropylatrazine, are among the most widely detected herbicide residues in surface
water and ground water.21

MATERIALS AND METHODS
The immunosorbents used in these examples were prepared using HPLC-grade
silica modified with a preparation of antibodies immobilized using the Schiff base
method or comparable technique.13

In the examples presented here, these

immunosorbents were tested and coupled on-line with either reversed-phase liquid
chromatography (RPLC) with ultraviolet (UV) detection or liquid chromatography-mass
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spectrometry (LC/MS) for detection and analysis of micro-constituents in water and other
aqueous matrices.
Figure 2-1 gives a schematic of the on-line immunosorbent column coupled to
RPLC pre-column configuration discussed in this chapter.11,

16, 22, 23

The system uses

three pumps and two switching valves to control flow between the immunosorbent
column and two reversed phase columns. A similar system has been used to study the
interfacing of immunosorbents with RPLC22 and in studies of the binding strengths and
kinetics of environmental contaminants as they bind to and elute from immunosorbents in
HPLC systems.24 In this type of system, a small column containing the immunosorbent is
first placed on-line with an appropriate application buffer as sample is injected onto the
system. The application buffer is typically a neutral pH aqueous buffer (e.g., pH 7-7.4
phosphate) that will allow strong binding to occur between the analytes in the injected
samples and immobilized antibodies in the immunosorbent column. After non-retained
sample components have been washed from the column, a valve is switched and the
immunosorbent is placed on-line with a small RPLC precolumn. An elution buffer is
pumped through the immunosorbent, releasing target compounds which are then retained
by the RPLC column. After the desired solutes have been recaptured by the RPLC
precolumn, the valve is then switched again and the RPLC precolumn is placed in series
with a longer analytical RPLC column. Mobile phase containing organic solvent is
passed through these two columns, which causes analytes to be eluted from the
precolumn and separated on the analytical column based on polarity. These solutes are
then detected as they elute from the analytical column and enter an appropriate detector.
While this separation is occurring, the application buffer is reapplied to the
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Figure 2-1.

A typical system for coupling an HPLC immunosorbent column on-line
with reversed-phase liquid chromatography and absorbance detection
(Reproduced with permission from Ref. 25).
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immunosorbent as this material is allowed to regenerate. The entire process is then
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repeated for the next sample injection. This type of analysis can be carried out using a
standard benchtop HPLC system.16, 22, 23 The same approach can also be modified as part
of a smaller field-portable system.25
A similar scheme to that shown in Figure 2-1 can be utilized for the on-line
coupling of LC/MS with immunosorbents. An example of one such system, which has
been used in the detection of carbamazepine in aqueous samples,26 is shown in Figure 22. The initial steps for operation in the system shown in Figure 2-2 are similar to those
already described in Figure 2-1. However, in Figure 2-2 the RPLC column is also used
for an intermediate step in which a switch is made from one type of aqueous buffer,
which is used for the release of solutes that have been retained by the immunosorbent
(e.g., pH 2.5 potassium phosphate buffer) to a more volatile buffer that is compatible with
the LC/MS system (e.g., acetate buffer). In this particular case, the RPLC precolumn is
used alone for the separation of solutes based on polarity once the second, more volatile,
buffer is combined with some organic modifier (e.g., acetonitrile). The eluting analyte is
then detected as it leaves the RPLC precolumn using an on-line mass spectrometer as the
detector.26 If desired, a second, longer RPLC column can also be placed after the RPLC
precolumn to aid in the separation of sample components based on their polarity.12
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Figure 2-2.

System for detecting an analyte by using an HPLC immunosorbent and
LC/MS (Based on results presented in Ref. 12).
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There are various ways for combining immunosorbents with other methods for
the analysis of micro-constituents. One method that can easily be coupled with the online use of immunosorbents is RPLC. The combination of immunosorbents with this
approach produces a method that has been referred to as immunoaffinity/RPLC, or IARPLC. There are several examples of the use of IA-RPLC for the analysis of microconstituents in the environment. This method has been employed as a tool in a number of
studies to measure atrazine and related degradation products in various types of water
samples.16, 23, 25 An example of how an immunosorbent can aid in such an analysis is
shown in Figure 2-3. The upper chromatogram in this figure shows the result that is
obtained when a groundwater sample is injected directly onto only a RPLC column. The
result is a chromatogram with a large number of peaks and a high background signal,
making atrazine undetectable because of other sample components. This illustrates the
difficulty in detecting trace levels of solutes such as atrazine at low parts-per-billion
levels in a complex matrix.
When the same sample is first allowed to pass through an immunosorbent column
selective for atrazine, the retained fraction that was then allowed to go on to the RPLC
column gave a much simpler chromatogram. In this second case the number of
background peaks is greatly reduced and it is now relatively easy to identify and quantify
2 ppb atrazine present in the original sample even when using a relatively nonspecific
UV-absorbance detector.
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Figure 2-3.

The analysis of atrazine in a groundwater sample by using only a RPLC
column (top) or an anti-atrazine immunosorbent column followed by the
same RPLC column (bottom). The detected atrazine was present in the
groundwater sample at a level of 2 parts-per-billion (Adapted with
permission from Ref. 25).
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In addition for use in measuring triazine herbicides,16, 23, 25 IA-RPLC has been
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used with carbofuran,27 carbendazim,28 and 2,4-D and related compounds.22, 24 An
analysis of carbendazim in soil and lake water employed a protein G column that was
coupled to a reversed-phase analytical column by using a restricted access media trapping
column. The limit of detection for carbendazim was 0.025 ppb and the throughput was
on the order of three samples per hour.28 In some of these studies, limits of detection in
the parts-per-billion and parts-per-trillion range have been reported even when using UV
absorbance detection after the immunoextraction and RPLC separation.16
The cross-reactivity of antibodies for structurally-similar compounds is often a
problem in immunoassays and related methods. However, this ability can be used in
work with immunosorbents and IA-RPLC to allow for the simultaneous analysis of
closely-related micro-constituents, such as a contaminant and its degradation products.
This approach has been used to measure the occurrence of atrazine and its degradation
products such as hydroxyatrazine, deethylatrazine and deisopropylatrazine using a single
IA-RPLC system. An example of one such system that was optimized for the analysis of
atrazine degradation products at low parts-per-trillion levels is shown in Figure 2-4. In
this method, the immunosorbent is used to selectively extract chemically-related
compounds, as opposed to a single compound, from a sample. The extracted compounds
are then separated based on their polarity by later releasing these chemicals from the
immunosorbent and passing them through one or more RPLC columns (e.g., a RPLC
precolumn and a large analytical column). This latter type of separation is particularly
useful in discriminating between a parent compound and its metabolites or degradation

29

Figure 2-4.

Separation and analysis of deisopropylatrazine (DIA), hydroxyatrazine
(HA), and deethylatrazine (DEA) by IA-RPLC. This result was obtained
for a 45 mL groundwater sample containing 60, 10 and 210 parts-pertrillion DIA, HA and DEA, respectively. (Reproduced with permission
from Ref. 16).
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products, which do tend to have large differences in polarity and which are relatively
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easy to examine simultaneously by such an approach.16, 23
A field-portable system for the analysis of triazine herbicides, 2,4dichlorophenoxyacetic acid (2,4-D) and related compounds in groundwater and surface
water has also been developed.25 No sample pretreatment besides filtering through a 0.2
µm syringe filter was necessary in this work before sample injection. The sample
analysis took 10 minutes or less and the detection limit for atrazine was near 0.3 ppb.
Other analytes with which IA-RPLC has been used include work that has been reported
with estrogens,29 polycyclic aromatic hydrocarbons,30, 31 isoproturon,32 phenylurea
pesticides,32-35 aflatoxins,36 E. coli37 and compounds related to azo dyes.38
Varying the position and function of the immunosorbent column, along with
adjustment of buffering conditions, are other options to consider when optimizing IARPLC methods as illustrated in the analysis of the herbicide 2,4-D.22 In this case, an
immunosorbent column for 2,4-D and related herbicides was followed by an RPLC
precolumn and an RPLC analytical column. Dissociation rates for these compounds as
they were eluted from the immunosorbent were first determined in the presence of
various buffers. The retention of these analytes on the RPLC precolumn was also
examined and this information was combined with that collected from the
immunosorbent for use in computer modeling of the IA-RPLC interface. A modified
countercurrent distribution model was used and found to give good agreement with the
experimental results. It was shown through this work that both the immunosorbent
column conditions and RPLC precolumn conditions could be adjusted in an IA-RPLC

system to adjust the selectivity of this method for a given analyte (e.g., 2,4-D) or for a
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group of analytes (e.g, 2,4-D and related compounds).
Although IA-RPLC can be used with absorbance detectors (e.g., see results in
Figures 2-3 and 2-4), immunosorbents have also been applied in a number of studies
with more sensitive instrumentation such as liquid chromatography mass spectrometry, or
LC/MS (e.g., see reviews in refs 12 and 13). An example of a general scheme that can be
used for on-line immunoextraction coupled with LC/MS was described in Figure 2-2.
This particular scheme involved the use of small immunosorbent columns to extract
carbamazepine prior to detection using LC/MS.26 This method used a small
immunosorbent column with the design that is shown in Figure 2-5. This column
consisted of two layers of an inert support that served as a mechanical support for an
immunosorbent active layer that was only 500 µm long with an inner diameter of 2.1
mm. The small size of this column made it inexpensive to prepare and practical for use
with even small amounts of immobilized antibodies. The same design could easily be
used to prepare other types of immunosorbents and can be used with either RPLC or
LC/MS systems.
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Figure 2-5.

Design of a housing for construction of microaffinity columns containing
an immunsorbent layer.39 (Reproduced with permission from Ref. 39).
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DISCUSSION
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The previous section gave several examples that illustrated the on-line use of
immunosorbents with RPLC or LC/MS for analysis of environmental contaminants. The
selectivity of antibodies has allowed these methods to be used with a wide variety of
samples that have included groundwater, surface water, drinking water, soil extracts, food
samples, and biological samples.12, 13 As shown in Figure 2-3, this selectivity allows
matrix components that are not similar to the analyte to be effectively removed before the
analyte is detected. This essentially lowers the background signal and helps to remove
potential interferences from the sample prior to analyte detection.
Although some cross-reactivity may still be present between the analyte and
structurally-related compounds in the sample, this effect can be used to an advantage.
This idea was illustrated in Figure 2-4, in which the combined use of an immunosorbent
and RPLC was used to first isolate a group of atrazine degradation products from a
sample and then to separate and simultaneously measure the degradation products as they
passed through the RPLC column.16 The same effect can be used in a single IA-RPLC
method to look at several closely-related herbicides, such as atrazine and simazine or 2,4D and related agents.22, 23
The strong binding of immunosorbents under physiological conditions allows
many of these materials to retain and concentrate their targets prior to their analysis. In
many cases, the antibodies in an immunosorbent will bind irreversibly to their target
compounds at a neutral pH and hold onto these until an appropriate elution buffer is
applied. The overall effect is that the size of the captured analyte fraction is more
directly related to the mass or moles of analyte that have been applied to the
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immunosorbent rather than to the concentration of this analyte.40 As a result, the use of a
large sample volume can be used to obtain lower concentration limits of detection for
RPLC and LC/MS systems that first use immunosorbents for sample pretreatment. The
result of such an approach was illustrated in Figure 2-4, in which the use of a 45 mL
sample volume made it possible to modify an IA-RPLC method for atrazine to allow for
low parts-per-trillion detection limits of its degradation products.16
There are several reasons why immunosorbents are commonly used with RPLC
columns in these methods. First, the aqueous elution buffers that are often used with
immunosorbents will act as weak mobile phases for RPLC columns. This property
means the retained chemicals that are released from an immunosorbent in the presence of
such a buffer will tend to bind strongly and be concentrated at the top of the RPLC
column. This effect tends to take the peak for the dissociating solutes that are leaving the
immubosorbent and focus the eluting mix into a narrow band, thus making it possible to
more easily later separate these chemicals on the RPLC column in the presence of an
appropriate mobile phase.22 The fact that a RPLC column provides a separation based on
the general property of chemical polarity is also useful in providing a complementary
scheme for isolating and resolving the chemicals that have been retained and
concentrated by the immunosorbent.12, 13

CONCLUSIONS
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This chapter has examined the use of immunosorbents with RPLC and LC/MS
and has considered several aspects of such methods. A number of examples from the
literature were provided to illustrate some of the useful features of immunosorbents in
work with environmental contaminants. It has been demonstrated in the literature that
immunosorbents can be effective tools in concentrating trace analytes from large sample
volumes, making it possible to obtain limits of detection at the parts-per-billion level or
even in the parts-per-trillion range. These methods have been used with a variety of
samples, such as groundwater, surface water, food, and biological samples. This
approach has promise for both laboratory and field-portable analytical methods for
organic micro-contaminants. A number of factors have also been considered in the
literature in the design and development of such systems, such as the conditions needed
for interfacing the immunosorbent with RPLC or LC/MS. The selective binding of
immunosorbents, their ability to be interfaced with LC or LC/MS/MS, and the ability to
obtain antibodies against a wide range of micro-constituents are all properties that should
continue to make this approach attractive as an alternative to other current analysis and
sample pretreatment methods for the capture and integrated sampling of microconstituents in water samples.
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PREPARATION, CHARACTERIZATION AND CHROMATOGRAPHIC
EVALUATION OF MOLECULARLY IMPRINTED POLYMERS FOR USE IN
THE ONLINE EXTRACTION OF TETRACYCLINE FROM WATER

INTRODUCTION
Emerging contaminants, as discussed in Chapter 1, include several classes of
veterinary pharmaceuticals. Antibiotics are often used in agriculture to treat and prevent
diseases, as well as to promote growth and feed efficiency in livestock operations.1-3 At
large animal-feeding operations many animals are within close proximity to each other,
enabling diseases to spread quickly and making the use of veterinary pharmaceuticals
necessary.2 There has been concern that the sub-therapeutic doses of antibiotics that are
used regularly for animals during food production are causing an increase in antibioticresistant bacteria.2 Antibiotic-resistant E. coli has been found in the waste of feedlot
animals that have been administered sub-therapeutic doses of antibiotics.4 In addition,
even though some antimicrobials that are used for animals are not always the same as
those used to treat disease and infection in humans, there is still the possibility of
bacterial resistance occurring to both types of antibiotics even given exposure of bacteria
to only one group of these drugs. The structures of the antimicrobials that are usually
employed for animals are similar enough to those used for humans to cause resistance to
more than one of these compounds.3
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Antibiotics are often poorly absorbed by an animal’s body and, depending on the
compound, most of the drug may be excreted unchanged from its original form.
Furthermore, antibiotic metabolites can also be bioactive. This situation poses an
environmental risk because it is common in many parts of the world to supplement
fertilizer with animal waste.2 Pharmaceuticals may also be present in wastewater from
feeding operations and make their way into groundwater and surface water.3
The focus of this research is on the tetracycline group because these are widely
used in cattle, pork and poultry production.3, 5 Tetracycline and macrolide antibiotics
make up more than 16% of all veterinary antibiotics in the U.S.1 The general structure of
tetracycline is shown in Figure 3-1.
In order to successfully detect antibiotics and other emerging contaminants in
environmental samples, effective pretreatment, extraction and concentration of these
agents from complex matrices is necessary. The required detection limits are low for
these analytes and these compounds must often be separated from interferences in the
sample.1, 3 Antibiotic analysis is most commonly performed by using liquid
chromatography-tandem mass spectrometry (LC/MS/MS). This method has the
combined advantages of good sensitivity, reproducibility and specificity.1 A common
method of extraction and concentration that is used prior to chromatographic analysis and
LC/MS/MS is solid phase extraction (SPE).3, 5 However, this method is not efficient for
samples with low concentrations of tetracyclines and requires multiple samplepreparation steps, often with the use of the standard addition method .3
Affinity extraction is an alternative to SPE, with the advantages of higher
selectivity, potentially less interference and faster sample processing than SPE.6

45
Immunoaffinity extraction, based on the use of antibodies, has been successfully used for
the extraction of analytes from various types of complex matrices both in off-line7-11 and
on-line12-15 configurations, including on-line extraction in a field-portable system.16
Detection limits have been obtained with this approach in the parts-per-trillion range for
off-line methods and in the parts-per-billion and parts-per-trillion range for on-line
methods. These low limits of detection can be reached because the affinity column is
mass sensitive and responds to the amount of analyte (i.e. moles, rather than the
concentration of the analyte).6 On-line immunoaffinity extraction has been combined
with reversed-phase liquid chromatography (RPLC) in the analysis of herbicides,
carbofuran and carbendazim and has been shown to give excellent reproducibility and
short analysis times in such an approach. On-line immunoextraction allows the transfer
of the analyte to occur more quickly and inexpensively than off-line methods, with
greater precision and recovery and with the use of fewer reagents.6
Molecularly imprinted polymers (MIPs) have been employed as alternatives to
antibodies in affinity supports. MIPs are easy to prepare, less expensive than antibodies
and can be used for a wider variety of analytes. For example, MIPs can be used with
nonaqueous samples and with analytes for which antibodies cannot easily be generated
(e.g., due to toxicity).6, 17 During the synthesis of MIPs, a binding site is created which
allows recognition and binding of a target molecule to take place later. The preparation of
MIPs, as illustrated in Figure 3-2, involves the polymerization of functional monomers in
the presence of a cross-linker and template, or imprint molecule. One or more functional
groups are chosen for the process based on the interactions that will take place between
these groups and the template molecule. A complex is formed between the imprint
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molecule and the functional monomers. Polymerization then is allowed to take place and
the cross-linked structure holds the functional groups in place. The template molecule,
which has been chosen based on the final desired target, is next extracted after formation
of the polymer. This leaves behind a binding site in the polymer that is capable of
recognizing and binding the target molecule. This type of recognition can occur because
the binding site has a size and shape that are complementary to those of the template and
target molecule.17
Another, recently developed option for affinity ligands is the use of aptamers.
These are oligonucleotides that are designed for binding to a specific target. They are
chosen from random single-stranded DNA and then enriched through the use of a
technique known as systematic evolution of ligands by exponential enrichment (SELEX).
They can be created for target proteins that do not bind to DNA and for a wide variety of
compounds.18
Although the most common applications of MIPs in separations has been the use
of these materials in SPE for processing food, environmental and medical samples; MIPs
have also been used in membrane extractions.17 In another example, MIPs were used in
affinity membranes to remove tetracycline from water.19 However, the use of MIPs as
affinity ligands in HPLC has been more limited because of the binding site heterogeneity
of these agents.17 However, the need for improved on-line extraction at a lower cost than
that possible with immunoaffinity columns makes MIPs an attractive alternative for such
an application.
This research investigated the use of various forms of MIPs as stationary phases
in HPLC. Bulk polymers were prepared and used in HPLC columns. Polymerization

was also attempted on silica particles that are used as chromatographic supports.
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Tetracycline was used as the template molecule and methacrylic acid (MAA) was used as
the functional monomer because it can form hydrogen bonds with tetracycline (see
structure in Figure 3-1).
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Figure 3-1.

The structure of tetracycline.19
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Figure 3-2.

The preparation of a molecularly imprinted polymer (MIP).
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EXPERIMENTAL
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Reagents
Tetracycline, methacrylic acid (MAA) and (3-aminopropyl)-triethoxysilane (APS)
were obtained from Sigma-Aldrich (St. Louis, MO). Ethylene glycol dimethacrylate
(EDMA) was obtained from Aldrich (Milwaukee, WI). 2-2‘-Azodi (2,4dimethylvaleronitrile) was obtained from Wako Pure Chemical Industries (Osaka, Japan).
HPLC-grade Nucleosil 1000-5 and 1000-7 silica (1000 Å pore size, 5 µm and 7 µm
diameter) were obtained from Macherey-Nagel (Düren, Germany). All other chemicals
were of the purest grades available. Solutions were prepared using water from a
Nanopure purification system (Barnstead, Dubuque, IA).
Apparatus
The chromatographic system used for the testing of MIP columns consisted of a
LC-10AT pump, two Advantage PF Valves, and aSPD-10AV UV-Vis detector from
Shimadzu (Kyoto, Japan). A Jasco (Easton, MD) PU-980i pump, a Thermo Separation
Products (Waltham, MA) Consta Metric 4100 pump and a Hitachi (Schaumburg, IL) L6000 pump were also used in testing the backpressure of columns. A Thermo Separation
Products Spectra Series (Fremont, CA) UV100 UV-Vis detector was also used.
Data were collected using software and an interface from National Instruments
(Austin, TX). All supports were downward-slurry packed using an HPLC column packer
from Alltech (Deerfield, IL).

Polymer Preparation
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Bulk polymer synthesis
A method previously used to prepare MIPs for tetracycline recognition in affinity
membranes19 was followed with some modifications. For instance, a different initiator
was used: 2-2‘-azodi (2,4-dimethylvaleronitrile) instead of azobis(isobutyronitrile)
(AIBN). The reaction mixture consisted of 9.95 g EDMA, 1.05 g MAA, 0.12 g initiator,
15 ml acetonitrile, 10 ml benzyl alcohol and 1.24 g tetracycline. The polymerization
reaction was carried out at 50 °C for 24 h. A control, or non-imprinted polymer (NIP)
was prepared following the same procedure, with the exception of the addition of
tetracycline. After grinding the material by using a mortar and pestle, the polymers were
dried and sieved to sort them with regard to size.
For the MIP that contained tetracycline, the fraction that was obtained by using a
25 µm sieve (≥ 25 µm and < 53 µm) was placed into a cellulose thimble and extraction
was carried out with this MIP at 100 °C for 11.5 days. The extraction solution was
changed to 10% acetic acid in acetonitrile twice and then replaced twice with 100%
acetonitrile. The extraction solvent was light orange and still appeared to be extracting
tetracycline after 11.5 days. The polymer was washed with water and packed into a 50
mm x 3 mm I.D. column and two 15 mm x 2.1 mm I.D. stainless steel columns. Because
the backpressure of the 50 mm x 3 mm I.D. column was too high for practical use,
acetonitrile was pumped through the 15 mm x 2.1 mm I.D. column at 0.1 ml/min for 20
hr to flush out any remaining tetracycline and to use this column. The NIP was similarly
packed into a 15 mm x 2.1 mm I.D. stainless steel columns after sieving.

Grafting of MIPs on silica particles
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A previously reported method was followed to prepare porous silica particles with
polymerization precursors attached to their surface.20 Nucleosil silica was reacted with
APS in various ways: under ambient conditions, under an inert atmosphere and using a
pyridine catalyst. IR spectra were obtained after reaction of the silica with APS and after
a second reaction between the silica-APS with azobiscyanovaleric acid (ACVA).
Chromatographic Conditions
Each polymer support was downward-slurry packed at 1500-3500 psi for 1-3 h
into separate 50 mm x 3 mm I.D. or 15 x 2.1 mm I.D. stainless steel columns. The
packing solvent was water. A Rheodyne (Oak Harbor, WA) Lab Pro valve was also used
for column packing. The flow rates during the HPLC experiments were 0.1, 0.2, 0.5, 1
and 5 ml/min. Samples of 5 µM , 20 µM and 50 µM tetracycline in water were injected
using a 5 µL sample loop onto the 15 mm x 2.1 mm I.D. column containing the
tetracycline imprinted polymer while using water as the mobile phase. The flow rates
were 0.2 and 0.5 ml/min for these injections and detection was carried out at a
wavelength of 275 nm.
Particle Size Distribution Evaluation
The NIPs were ground for 10 min or 20 min using a mortar and pestle, dried in a
vacuum oven overnight at room temperature, and sieved for 20 min to separate according
to particle size using a Tyler (Mentor, OH) sieve shaker. Alternatively, the polymers
were ground for 10 min using an Angstrom (Belleville, MI) pulverizer. Pictures were

taken of the NIP under a light microscope to determine the range of particle sizes that
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were included in a given size range after processing by using the sieves and sieve shaker.

RESULTS AND DISCUSSION
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As noted earlier the extraction solvent used to treat the final MIPs became light
orange and appeared to be extracting tetracycline from these polymers even after 11.5
days. The difficulty of extracting the template molecule is a common problem during the
preparation of MIPs. This problem often occurs because some of the template is buried
deep in the polymer.17 Unfortunately, even with successful extraction, the low
accessibility for many of the remaining binding sites can be problematic in HPLC
applications of the resulting MIPs.17 After further flushing the 15 mm x 2.1 mm I.D. MIP
column with acetonitrile using an HPLC pump, the solvent was then colorless, indicating
that no further tetracycline was being removed from the polymer after this treatment.
This size of column was used in all further studies because the back pressure of a similar
50 mm x 3 mm I.D. tetracycline MIP column was too high for practical use.
In initial testing of the 15 mm x 2.1 mm I.D. column, a large peak was observed
almost immediately following each injection of tetracycline, which may have been due to
overloading of the column. However, there was also a broad peak with a retention time
of 40 min which was believed to be due to the retention and later elution of tetracycline.
Further injections of tetracycline samples produced no observable peaks when water,
acetonitrile and combinations of both solvents were used as the mobile phase.
Acetonitrile works well as a mobile phase for MIPs based on methacrylic acid. These
polymers are also resistant to this solvent.21 When acetonitrile was used to regenerate the
column, the solvent was clear, indicating that no appreciable amount of retained
tetracycline was eluting under these conditions. A second 15 mm x 2.1 mm I.D. column

was then packed with the same tetracycline MIP, but the back pressure of this second
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column quickly reached the pump’s limit during testing.
The effect of particle size on column performance was examined by preparing 15
mm x 2.1 mm I.D. columns that contained NIPs of various sizes. The 25-45 µm fraction
of the NIPs appeared to have a back pressure that was lower than typical column back
pressures. This may have been due to inefficient packing of that particular column since
all of the other fractions (<25 µm, ≥25 µm and <45 µm, ≥45 µm and <53 µm, ≥53 µm
and <106 µm, ≥ 106 µm) gave backpressures that were too high. The limit of the HPLC
pump was either reached or the pump was stopped in order to prevent reaching the upper
pressure limit in each of these cases. A possible explanation for the high back pressures
seen with these supports was that the frits at the column ends became clogged. This may
have been the case if small particles were attached to larger ones and stayed in the larger
size fraction during the sieving process. This hypothesis was possibly confirmed when
the packing of a NIP column was attempted by using a valve and HPLC pump instead of
a slurry packer. Injections of the NIP slurry were made and the back pressure quickly
reached the upper limit. When the column was removed, there was no packing visible
inside except for a small amount of slurry that was found on the frit at the bottom. If fine
particles were attached to larger ones and stayed in the sieved fraction for larger particles,
they would have clogged the frit during the packing process and led to this type of
behavior.
When examined under a microscope, the NIPs from the >106 µm and 53-106 µm
size fractions contained a significant amount of fine powder. These small particles were
believed to be the source of the clogged frits and high back pressures that were seen
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during the column packing process. As shown in Figure 3-3, longer and higher intensity
grinding of the NIPs gave smaller particle sizes. Although grinding ensured more
uniform particle sizes were present, as would be desirable for HPLC supports, this
approach also introduced unwanted fine particles. For instance, Figure 3-4 shows a
picture of the NIPs in the 53-106 µm size fraction sieve after it was allowed to settle in
water for 1 day.
Wet-sieving was done in an effort to remove fine particles. It appeared successful
in this respect but the particle sizes seemed irregular under the microscope. Grinding
afterwards seemed to reintroduce some unwanted fine powder. However, dry sieve
shaking for 60 min appeared to remove fine particles, even though the particle size
distribution seemed fairly large for the >106 µm fraction NIP. This distribution appeared
more uniform for the 53-106 µm fraction. Wet sieving followed by grinding and
extended dry sieving appeared to give the best particle size distribution while also
excluding fine powder from the final preparation.
Because it can be difficult to obtain MIPs that are suitable for chromatography
through the use of bulk polymerization techniques, alternative methods of preparation
were sought in this study. Crushing and sieving procedures can result in a large loss of
material and destruction of binding sites and, although resulting MIPs can have high
affinity and selectivity, they often suffer from low capacity and poor site accessibility.
Ideally, the preparation method should give a high yield of particles with a uniform pore
size and particle size distribution that does not depend on the monomers, template
molecules, or solvents that are used.22, 23
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Figure 3-3.

Particle size distribution of tetracycline molecularly imprinted polymer.
Typical precision for these measurements was 0.003-0.14%.
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Figure 3-4.

Image seen under a light microscope for the 53-106 µm fraction of a NIP.
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In a previously reported method, the grafting of polymerization azo initiators onto
silica was carried out, followed by the synthesis of MIP films on the silica particles.22 In
an attempt to create MIPs that were suitable for the on-line extraction of tetracycline, the
grafting reaction of (3-aminopropyl)-triethoxysilane (APS) to silica support particles was
next carried out in this study. This reaction was conducted under ambient conditions,
under an inert atmosphere, and with a pyridine catalyst. A representative IR spectrum of
the silica-APS that was prepared under inert atmosphere is shown in Figure 3-5. The two
small NH2 bands, interpreted as being the result of hydrogen bonding between the amine
group and unreacted silanol groups,20 were absent at 3301 and 3352 cm-1. It is possible
that the yield in this case was higher than that obtained in Ref. 19 and that there were few
remaining silanol groups; it is also possible that condensation of the APS had taken place
because of a trace amount of moisture that may have been present,20 thus giving a low
yield of silica APS.
The silica APS was further reacted with the initiator azobiscyanovaleric acid
(ACVA) in order to anchor this agent to the particle’s surface for use in future
polymerization reactions. The IR spectrum obtained after this reaction is shown in Figure
3-6 and is compared to the spectrum for this product that was obtained in Ref. 19. The
stretching vibrations of the amide groups are absent in this new IR spectrum.
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Figure 3-5.

IR spectrum of silica APS synthesized under an inert atmosphere (top), as
compared with a spectrum from Ref. 19 (reproduced with permission,
bottom).
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Figure 3-6.

IR spectrum of silica APS ACVA synthesized under an inert atmosphere
(top), as compared with a spectrum from Ref. 19 (reproduced with
permission, bottom).
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CONCLUSIONS
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This study explored MIP preparation for use in the on-line extraction of
tetracycline for HPLC. Although some results indicated that an MIP for this analyte
could be produced and that it had reasonably high retention for tetracycline, the resulting
support often gave high back pressures and was difficult to use in making reproducible
columns. The high backpressures appeared to be a result of bulk polymerization methods
and the generation of fine particles that seemed to attach to larger particles and follow
with the larger particles though a sieving process. Wet sieving followed by extended dry
sieve shaking may have removed most of these fine particles and allowed a more uniform
particle size of the MIPs to be maintained.
An alternative approach based on the synthesis of MIPs on silica particles was
also pursued. A comparison of IR spectra for the intermediates and products from this
synthesis differed with reference spectra from the literature. However, this may have
been due to low recoveries of the product or the presence of trace amounts of water in the
reagents or starting materials. Future optimization of this approach is also needed.
Other possible strategies for MIP synthesis include multi-step swelling
polymerization, suspension polymerization and precipitation polymerization. These
techniques have produced spherical MIPs with uniform sizes that are well suited for
chromatographic applications.23
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COMPARISON OF VARIOUS α1-ACID GLYCOPROTEIN IMMOBILIZATION
METHODS FOR USE IN THE SEPARATION OF RACEMIC MIXTURES OF
PHARMACEUTICAL AGENTS

INTRODUCTION
The chiral separation of pharmaceutical agents is important in the development
and production of drugs because often only one enantiomer is active while the other can
have unwanted side effects and no beneficial activity.1 Although there are regulations
requiring production of the desired enantiomer or separation of enantiomers, no process
is completely efficient. It is necessary to monitor industrial production of
pharmaceuticals to ensure enantiomeric purity.2 In addition, some drugs are used as
racemic mixtures and their stereochemistry affects their pharmacological action and
toxicity.3 Also, the ability to measure the relative amounts of the chiral forms of drugs in
plasma and urine samples can provide useful pharmacokinetic information and can
indicate whether one drug form is more effective than another.1
α1-Acid glycoprotein (i.e., orosomucoid or AGP) immobilized to chromatographic
supports has been used effectively in chiral separations for a wide variety of compounds,
such as benzodiazepines,4 non-steroidal anti-inflammatory drugs (NSAIDs),5 calcium
antagonist drugs6 and β-receptor blocking agents.7 Separations in AGP columns can be
adjusted by adding low concentrations of alcohol to the mobile phase and by varying the

pH.1, 8 AGP provides better retention and resolution for many chiral drugs than other
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proteins because of AGP’s higher affinity for the compounds to which it binds.8
AGP is an important component of blood plasma and has a molecular mass of
approximately 41,000 g/mol.1, 8, 9 It is produced by the liver and is involved in
transporting various substances in the body. It is thought to be involved in the immune
response because its levels rise during many disease states.8 The structure of AGP
consists of a single polypeptide chain made up of 181 amino acids and five carbohydrate
groups. Of all the potential ways the carbohydrate groups can be attached to AGP, only
12 to 20 combinations have been detected. Disease states also affect the extent of AGP
glycosylation as well as the arrangement of the carbohydrate groups, which may
influence binding by this glycoprotein to drugs.8
There is interest in the chromatographic resolution of racemic mepivacaine and
other drugs by companies such as Regis Technologies, Inc. (Morton Grove, IL).
Mepivacaine is a local anesthetic that is used as a racemic mixture.3 To meet this need,
several methods for the immobilization of AGP onto silica were tested in this chapter for
preparing columns for these types of separations. One method that has been reported for
the immobilization of AGP was developed by Xuan and Hage;10 this method involves the
mild oxidation of the carbohydrate regions of AGP to generate aldehyde groups, which
are then used for the immobilization of AGP to hydrazide-activated silica. Figure 4-1
shows the reaction scheme for this approach. This immobilization method for AGP was
developed to create protein supports that show good agreement with the drug binding
behavior of AGP in solution.10
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Figure 4-1.

(A) Oxidation of AGP by periodic acid, (B) preparation of hydrazideactivated silica, and (C) immobilization of oxidized AGP to hydrazideactivated silica. Reproduced with permission from Ref. 10.
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A European patent by Hermansson1 describes two other methods which have also
been employed for the immobilization of AGP to supports such as silica. These two
methods, also based on the oxidation of AGP, were investigated in the research described
in this chapter. Stationary phases resulting from use of these methods have been used for
chiral separations involving the drugs disopyramide, mepensolate bromide, RAC 109,
bupivacaine, mepivacaine, propiomazine and oxyphencyclimine.1 The first of these
methods involves oxidation of the alcoholic hydroxyl groups of AGP, followed by crosslinking of this glycoprotein to itself and immobilization to a support that contains a
tertiary amine or quaternary ammonium groups. The steps involved are illustrated in
Figure 4-2. In this approach, the positive groups on an amine-containing support attract
the protein’s negative acidic groups that are present at the pH employed for
immobilization. The second approach by Hermansson involves covalent coupling of
amine groups on AGP to epoxide-activated silica,1 as shown in Figure 4-3. The first
method by Hermansson has been reported to produce a greater final protein content than
the second method, but both techniques were evaluated in this work for use in chiral
separations for the drugs of interest.
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Figure 4-2.

(A) Oxidation of AGP by periodic acid, (B) adsorption of AGP to N,N’diethylaminopropyl silica, and (C) cross-linking of AGP on the support.
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Figure 4-3.

(A) Preparation of epoxide-activated silica and (B) immobilization of
AGP to this type of support.
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Reagents
Lucifer yellow CH (LyCH), ethylene glycol, periodic acid, sodium metaperiodate,
oxalic dihydrazide, glycerol, sodium borohydride, glycidylpropyltrimethoxysilane (GPS),
racemic propranolol and mepivacaine were obtained from Sigma-Aldrich (St. Louis,
MO). Nucleosil 300-5 silica (300 Å pore size, 5 µm diameter) was obtained from
Macherey-Nagel (Düren, Germany). N,N-Diethylaminopropyl silica was obtained from
ES Industries Chromega Columns (West Berlin, NJ). All other chemicals were of the
purest grades available. All solutions were prepared using water from a Nanopure
purification system (Barnstead, Dubuque, IA). Human AGP was obtained from Sigma
(St. Louis, MO) and had a purity of at least 99%.
Apparatus
Slide-A-Lyzer 7K dialysis cassettes (7,000 MW cutoff) were purchased from
Pierce (Rockford, IL). Econo-Pac 10DG disposable, prepacked desalting gravity flow
columns were obtained from BioRad (Hercules, CA). The chromatographic system
consisted of a LC-10AD solvent delivery system from Shimadzu (Kyoto, Japan), a
LabPro injection valve from Rheodyne (Oak Harbor, WA) and a UV-2075 Plus
Intelligent absorbance detector from Jasco (Easton, MD). Data were collected using
software and an interface from National Instruments (Austin, TX). Data analysis was
performed using Peak Fit (SeaSolve Software). All supports were downward-slurry
packed using an HPLC column packer from Alltech (Deerfield, IL).

AGP Immobilization Method 1
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Oxidation of AGP
The first procedure for immobilizing AGP was based on that described by Xuan
and Hage (Figure 4-1).10 To oxidize AGP for this immobilization method (see Figure 41A), 14 mL of a 5 mg/ml solution of AGP were prepared in pH 7.0, 20 mM sodium
acetate buffer containing 0.15 M sodium chloride. This solution was combined in a 1:1
(v/v) ratio with 20 mM periodic acid in the same buffer, and the AGP was allowed to
react with the periodic acid at room temperature in the dark. After 15 min, the oxidation
of AGP was quenched by adding 7 mL of ethylene glycol (i.e., 0.25 mL ethylene glycol
per milliliter sample). After 2 min, dialysis was carried out on this mixture for 2 h at 4
°C against 2 L of pH 7.0, 20 mM sodium acetate buffer containing 0.15 M sodium
chloride. Three more dialysis cycles were carried out against fresh 2 L portions of pH
7.0, 0.10 M potassium phosphate buffer, with each dialysis cycle being conducted for 2 h
at 4 °C. AGP that was prepared using this procedure has been previously reported to
have an average of five aldehyde groups generated per AGP molecule.10

Immobilization of AGP
Hydrazide-activated silica was prepared as described by Ruhn et al.11, as
illustrated in Figure 4-1B. Oxidized AGP was immobilized to the hydrazide-activated
silica by using the procedure that is summarized in Figure 4-1C. The hydrazide-activated
silica (roughly 3.6 g) was placed in 12 mL of pH 7.0, 0.10 M potassium phosphate buffer
and sonicated under vacuum for 15 min to remove any air bubbles. A 40 mL portion of

approximately 2 mg/mL oxidized AGP in pH 7.0, 0.10 M potassium phosphate buffer
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was added to the silica slurry, and the resulting suspension was split into two equal
portions. Each portion was sonicated under vacuum for 5 min. The test tubes containing
these suspensions were placed onto a shaker and the immobilization reaction was allowed
to take place at 4 °C. After 3 days, shaking was stopped, the reaction mixture was
centrifuged, and the supernatant was removed. The silica was washed four times with pH
7.0, 0.10 M potassium phosphate buffer and four times with deionized water. Any
remaining hydrazide groups were neutralized by adding 3.4 g of glyceraldehyde, which
represented a 670-fold excess of glyceraldehydes versus the support’s original hydrazide
content.11 The resulting mixture was shaken for 6 h at 4 °C and then washed four times
with pH 7.0, 0.10 M potassium phosphate buffer and stored in this buffer at 4 °C until
use. The final amount of immobilized AGP was estimated by a protein assay to be 15.8
mg protein/g silica.10

AGP Immobilization Method 2
The procedure for this approach was a modified version of Method 1 by Xuan and
Hage.10 One change made was that only 4.52 mL of a 5 mg/ml AGP solution was
prepared for oxidation, with the amounts of 20 mM periodic acid solution and ethylene
glycol being adjusted accordingly. In addition, instead of using four dialysis cycles to
purify the AGP following the oxidation step, a desalting step was performed followed by
two dialysis cycles. The buffer used for desalting was pH 7.0, 20 mM sodium acetate
buffer that contained 0.15 M sodium chloride. Dialysis was performed for 2 h against pH

7.0, 0.10 M potassium phosphate buffer at 4 °C and then overnight under the same
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conditions. In the remainder of this method, 1.13 g of hydrazide-activated silica were
used for immobilization, along with 10.5 ml of the oxidized AGP solution. The
immobilization reaction was allowed to take place for 3.5 days and the amount of
glyceraldehyde that was added made up a 200-fold excess versus the support’s original
hydrazide content.11

AGP Immobilization Method 3
The procedures followed in this method have previously been described in the
patent by Hermansson.1 In this method, 50.65 mg of AGP were placed into 10 mL of pH
5.05, 0.01 M sodium acetate buffer and kept at 4 °C. A 0.03 g portion of sodium
metaperiodate was then added, giving a 120-fold mol excess of the metaperiodate versus
AGP. This mixture was allowed to react for 1 h in the dark at 4 °C. Glycerol was then
added in a 19-fold mol excess versus metaperiodate to quench the oxidation reaction and
was allowed to react with the mixture at room temperature for 10 min. The AGP was
purified using disposable desalting gravity flow columns containing pH 5.0, 0.01 M
sodium acetate buffer. The purified AGP in the pH 5.0 buffer was then mixed with 2.5 g
of N,N’-diethylaminopropyl silica, as supplied by Regis Technologies. According to
Hermansson, this step should have resulted in the adsorption of AGP to the surface of the
N,N’-diethylaminopropyl silica through ionic interactions. 1 After allowing this
adsorption to occur for approximately 3 h, the silica was centrifuged and washed three
times with 0.03 M, pH 9.2 borate buffer. The pH was raised in this step so that the amino
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groups in the peptide chain of AGP would be mainly present in a neutral form that could
undergo a cross-linking reaction with aldehyde groups on the oxidized carbohydrate
regions of adjacent AGP molecules. 1 This cross-linking reaction and immobilization
step was allowed to continue at 4 °C in the dark and with continuous shaking for
approximately 17 h. The silica was then washed with pH 8.5, 0.1 M borate buffer and
reacted with excess sodium borohydride at room temperature to reduce the remaining
aldehyde groups and convert the Schiff bases that formed during cross-linking into stable
secondary amine linkages.

The final support was washed three times with pH 7.0, 0.10

M potassium phosphate buffer and stored in this buffer at 4° C until use.

AGP Immobilization Method 4
The procedure followed in this approach was the same as in Method 3 by
Hermansson1 but used twice the amount of AGP for the immobilization process.

AGP Immobilization Method 5
This approach was also one of the methods that has been previously described by
Hermansson and involved the covalent coupling of AGP to silica particles.1 In this
method, 2.5 g of Nucleosil 300-5 silica were first reacted with 3-glycidoxypropyltrimethoxysilane in pH 5.5, 0.01 M sodium acetate buffer at 90 °C for 5 h. The resulting
epoxide-activated silica was reacted with 103 mg AGP in a pH 8.5 buffer; immobilization
in this buffer was allowed to take place for 41 h at 4 °C. The amounts of reagents that

were used in these steps were all selected based on similar and previously-described
methods for other proteins.10
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The final support was washed several times with pH 7.0,

0.1 M potassium phosphate buffer and stored in this buffer at 4 °C prior to use.

Chromatographic Conditions
Each AGP silica support was downward-slurry packed at 4000-4500 psi for 1-5 h
into separate 100 mm x 4.0 mm I.D. or 36 mm x 2.1 mm I.D. stainless steel columns.
The packing solution was pH 7.0, 0.10 M potassium phosphate buffer. The injected
samples had a volume of 5 µL. The flow rate was 1 ml/min, unless otherwise indicated.
The mepivacaine and propranolol samples each had a concentration of 100 µM and were
prepared in corresponding mobile phase. The mobile phase was pH 7.0, 0.10 M
potassium phosphate buffer; pH 7.0, 0.01 M sodium phosphate buffer; or pH 7.0, 0.01 M
sodium phosphate buffer containing 9% isopropyl alcohol. The detection wavelength for
mepivacaine was 210 nm and the detection wavelength for propranolol was 225 nm.
Each sample was injected in triplicate, unless otherwise indicated, and an average was
taken for retention times used in the calculation of retention factors and other parameters.
All experiments were performed at room temperature.

RESULTS AND DISCUSSION
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The following section summarizes the results that were obtained for each of the given
immobilization methods when the corresponding AGP columns were tested for use in the
chiral separation of mepivacaine or propranolol.
Method 1
A 100 mm x 4.0 mm I.D. AGP column that was prepared using Method 1 was
evaluated using one sample that contained 100 µM racemic propranolol and that was
injected onto the column in the presence of pH 7.0, 0.10 M potassium phosphate buffer at
1.0 ml/min and room temperature. When these conditions were used along with a
detection wavelength of 225 nm, a separation of the enantiomers was observed for
propranolol. The peaks were quite broad, as is common for such columns under aqueous
conditions; however, close to baseline resolution was obtained, with retention times of
approximately 68 and 99 min and retention factors of 62 and 91 for the two
enantiomers. This behavior indicated that the AGP column prepared by Method 1 had
both strong retention and good stereoselectivity for these two enantiomers in the presence
of only a pH 7.0 phosphate buffer.
The results for this method were in general agreement with those seen in a
previous study for the same type of AGP column in which separation of propranolol was
carried out under similar conditions with some organic modifier also being present in the
mobile phase. In that study, a 50 mm x 4.1 mm I.D. column was used along with a
mobile phase that consisted of pH 7.4, 0.067 M potassium phosphate buffer containing
2% (v/v) 2-propanol, operated at a temperature of 37°C and a flow rate of 2.0 ml/min.12
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It was interesting to note in comparing these conditions that the addition of 2-propanol to
the mobile phase acted to decrease the degree of retention while also sharpening the
peaks for the two enantiomers of propranolol. However, the addition of 5% (or more)
propanol gave rise to a sufficiently low retention for propranolol that no separation was
then observed for the separate enantiomers of this drug.12
When the same column was used by Regis Technologies for separation of the
enantiomers for mepivacaine, no resolution of these chiral forms was initially noted (the
retention time was 6.4 min and the retention factor was 4.8).

Mepivacaine was chosen

by Regis for this work because it has been noted in work with other types of protein
columns that is more difficult to achieve chiral separation for this compound than for
other drugs. The mobile phase used for this separation was 9% 2-propanol in pH 7.0,
0.01 M sodium phosphate buffer, which is typically used by this company for chiral
separations on AGP columns. The mepivacaine sample was prepared in this mobile
phase and was injected onto the column at a flow rate of 0.9 ml/min at room temperature.
The lack of a chiral separation in this case was not surprising, given the lack of
stereoselectivity that was previously noted for propranolol when using a mobile phase
that contained more than 5% 2-propanol.
Method 2
A second group of columns were prepared using Method 2, in which the same
general immobilization scheme was employed as in Method 1 but now modifying this
approach to yield a higher protein on the final support. Two columns were prepared
using Method 2; a 100 mm x 4.0 mm I.D. AGP column and a 36 mm x 2.1 mm I.D. AGP

column. For the 100 mm x 4.0 mm I.D. column, the mepivacaine and propranolol
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samples were analyzed under three different conditions. First, 100 µM samples of each
drug were prepared in pH 7.0, 0.10 M potassium phosphate buffer, which was also used
as the mobile phase. Two samples of propranolol and three samples of mepivacaine were
injected. Under these conditions, a separation was achieved for both compounds, as
shown in Figures 4-4 and 4-5 for propranolol and mepivacaine, respectively. The
selectivity factor for propranolol was 1.11 and the resolution between the peaks for its
enantiomers was 0.85 (the retention times were 82 and 90 min and the retention factors
were 74 and 82). The corresponding selectivity factor and resolution for the mepivacaine
peaks were 1.43 and 1.11, respectively, along with retention times of 10 and 14 as well as
retention factors of 8.1 and 12. These results indicated that a slightly modified form of
the method of Xuan and Hage10 could be used to prepare an AGP column that allowed
the chiral separation of either propranolol or mepivacaine in the presence of a pH 7.0
buffer alone and at room temperature.
The samples were next injected onto the 100 mm x 4.0 mm I.D. column in the
presence of pH 7.0 phosphate buffer after rinsing this column with water. This rinsing
step was done to determine whether water could be used as a storage solution for such a
column without affecting the ability to later use the column for a chiral separation. It was
found that both of the tested drugs again gave a chiral separation on the tested column
(e.g., see Figure 4-6). The selectivity factors and the resolution improved slightly for
both drugs (the selectivity factors increased by 0.7 and 0.1 for propranolol and
mepivacaine, respectively and the resolution increased by 0.3 and 0.2 for propranolol and

mepivacaine, respectively) after the rinsing step, which may have reflected the removal
of some remaining reagents after the immobilization step.
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Figure 4-4.

Chiral separation of propranolol using a 100 mm x 4.0 mm I.D. AGP
column prepared using Method 2. The sample was prepared in pH 7.0,
0.10 M potassium phosphate buffer, which was also used as the mobile
phase. Other conditions are given in the text.
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Figure 4-5.

Chiral separation of mepivacaine using a 100 mm x 4.0 mm I.D. AGP
column prepared using Method 2. The sample was prepared in pH 7.0,
0.10 M potassium phosphate buffer, which was also used as the mobile
phase. Other conditions are given in the text.
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Figure 4-6.

Chiral separation of mepivacaine on a 100 x 4.0 mm AGP column
prepared by using Method 2 and after rinsing with water. The sample was
prepared in pH 7.0, 0.10 M potassium phosphate buffer, which was also
used as the mobile phase. Other conditions are given in the text.
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After another rinsing step of the 100 x 4.0 mm AGP column with water, samples
of propranolol and mepivacaine were prepared and injected (one mepivacaine sample
was injected) in the presence of pH 7.0, 0.010 M sodium phosphate buffer that contained
9% isopropyl alcohol. This solvent composition was again chosen because of its routine
use by Regis in the evaluation of chiral columns. As mentioned previously, it is known
that chiral separations using proteins such as AGP are affected by the addition of small
amounts of organic modifiers in the mobile phase.2, 13 For instance, placing organic
modifiers such as 2-propanol in the mobile phase has been shown to affect the binding of
propranolol to AGP to a greater extent than changes in pH, ionic strength or
temperature.10 This can be explained by the fact that hydrophobic interactions are
important in the binding of propranolol to AGP, which involves nonpolar residues on the
protein.12
Figure 4-7 shows that propranolol was not resolved in the presence of pH 7.0
phosphate buffer and 9% 2-propanol for the 100 x 4.0 mm AGP column that was
prepared using Method 2 (the retention time was 37 min and the retention factor was 33).
This result was expected based on the results that were obtained with Method 1.10
However, a partial resolution of the mepivacaine enantiomers was observed under these
conditions (Figure 4-8) with retention times of 4.9 and 5.2 min and retention factors of
3.5 and 3.8. Uncharged modifiers added to the mobile phase usually result in reduced
retention and increased efficiency but also in loss of chiral separation.14 In this case,
reduced retention was observed along with an increase in efficiency for mepivacaine. For
both drugs, the separation factor decreased with increasing 2-propanol content, which

resulted in a loss of chiral selectivity. Such an effect can be explained by a possible
change in conformation for AGP.12
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Figure 4-7.

Injection of racemic propranolol on a 100 x 4.0 mm AGP column prepared
using Method 2 and in the presence of pH 7.0, 0.010 M sodium phosphate
buffer that contained 9% isopropyl alcohol. Other conditions are given in
the text.
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Figure 4-8.

Injection of racemic mepivacaine on a 100 x 4.0 mm AGP column
prepared using Method 2 and in the presence of pH 7.0, 0.010 M sodium
phosphate buffer that contained 9% isopropyl alcohol. Other conditions
are given in the text.
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A short 36 mm x 2.1 mm I.D. AGP column was also prepared using Method 2 for
the initial screening of binding by drugs to the AGP column. This column was evaluated
by using 100 µM samples of mepivacaine or propranolol that were injected into the
presence of pH 7.0, 0.10 M potassium phosphate buffer. On this short column, there was
retention for both drugs but little or no resolution was observed. The chromatogram for
mepivacaine (Figure 4-9) gave only a slight separation of enantiomers (the selectivity
factor was 1.23, the retention times were 0.8 and 0.9 and the retention factors were 1.1
and 1.3). An injection of racemic propranolol gave only a single peak for its
enantiomers, with a retention time of 7.1 and a retention factor of 17.1. The lower
resolution on this column was expected because it had a much smaller number of
theoretical plates than the 100 mm long AGP column. However, the short column was
found to be useful to quickly screen the effects of mobile phase composition on the
binding of drugs such as mepivacaine or propranolol to immobilized AGP.
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Figure 4-9.

Injection of mepivacaine on a 36 mm x 2.1 mm I.D. AGP column that was
prepared using Method 2. The sample was prepared in pH 7.0, 0.10 M
potassium phosphate buffer, which was also used as the mobile phase.
Other conditions are given in the text.
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For the evaluation of the 100 mm x 4.0 mm I.D. AGP column that was prepared
using Method 3, samples were made using both pH 7.0, 0.010 M sodium phosphate
buffer and 9% isopropyl alcohol in pH 7.0, 0.010 M sodium phosphate buffer. The
mobile phase for all of these samples was 9% 2-propanol in pH 7.0, 0.010 M sodium
phosphate buffer. Under these conditions, there was no separation observed for
propranolol. There did not appear to be any separation for the mepivacaine sample
(Figure 4-10). There was a decrease in retention for both compounds when 9% 2propanol was used in the mobile phase. For propranolol, retention times decreased from
2.7 to 2.0 min and retention factors decreased from 1.5 to 0.8. For mepivacaine, retention
times decreased from 2.3 min to 1.7 min while retention factors decreased from 1.1 to
0.5.

Method 4
The column prepared using Method 4 contained twice as much AGP as the
support prepared using Method 3. Although there was no separation for the propranolol
sample on this column (retention time was 4.2 min and retention factor was 2.9), it did
give some separation for the mepivacaine sample, with a retention time of approximately
2.5 min and a retention factor of 1.3. The latter separation was better than the results for
the column prepared using Method 3. The chromatogram for mepivacaine on the column
that was prepared by Method 4 is shown in Figure 4-11. The samples were again
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prepared in pH 7.0, 0.01 M sodium phosphate containing 9% 2-propanol, which was also
used as the mobile phase.
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Figure 4-10. Injection of mepivacaine on a 100 mm x 4.0 mm I.D. column prepared
using Method 3. The sample was prepared in pH 7.0, 0.010 M sodium
phosphate buffer containing 9% isopropyl alcohol, which was also used as
the mobile phase. Other conditions are given in the text.
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Figure 4-11. Injection of mepivacaine on a 100 mm x 4.0 mm I.D. column prepared
using Method 4. The sample was prepared in pH 7.0, 0.010 M sodium
phosphate buffer containing 9% isopropyl alcohol, which was also used as
the mobile phase. Other conditions are given in the text.
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A 100 mm x 4.0 mm I.D. AGP column was also prepared by Method 5. This
column was evaluated using the same separation conditions as already described for
Methods 3 and 4. However, in this case no separation was noted for either the
enantiomers of propranolol (retention time of 10 min, retention factor of 8.6) or
mepivacaine (retention time of 3.4 min, retention factor of 2.1).

CONCLUSIONS

Method 2, based on a modified procedure adapted by Xuan and Hage10 gave the
best results for the separation of the tested drug enantiomers. When pH 7.0 phosphate
buffer was used as the mobile phase in the absence of other additives, the separation of
enantiomers for both mepivacaine and propranolol was accomplished. However, the
addition of 9% 2-propanol resulted in a loss of chiral separation for propranolol and a
large decrease in chiral selectivity for mepivacaine on such a column. Method 1 gave the
next best results, with separation of propranolol but not mepivacaine. Method 4 gave
partial separation of the enantiomers of mepivacaine. Method 3 also gave partial
separation for mepivacaine.
In previous work, an increase in temperature has been observed to decrease
affinity.10 It is more difficult to predict the effects of temperature on chiral separations,
although there is evidence that affinity decreases for both enantiomers of propranolol
with temperature and that the affinity of AGP for S-propranolol is greater than that for Rpropranolol.10
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DEVELOPMENT OF AFFINITY SORBENTS FOR ON-LINE EXTRACTION
AND CONCENTRATION OF BIOLOGICALLY-ACTIVE CONTAMINANTS
FROM WATER
INTRODUCTION
Chapter 1 introduced the problem of emerging contaminants and outlined the
need to develop selective and efficient methods for their extraction from environmental
samples. These non-traditional pollutants include pharmaceuticals, steroid hormones and
many other organic compounds. Steroid hormones and other natural and synthetic
compounds that can mimic these hormones are considered endocrine disrupting
compounds because they interfere with hormonal systems in humans and animals. Some
examples are natural estrogens, natural androgens, phytosteroids, isoflavenoids, synthetic
estrogens, pesticides, phthalates, bisphenol A, dioxins and organotins.1 Some of these
agents are known to disturb the reproductive systems of aquatic organisms when present
at ng/L concentrations.2
Biologically active environmental pollutants are often present at quite low
concentrations (i.e., ng/L or even pg/L levels) and are often found incorporated within
complex matrices such as bio-solids or sludge, sediments, manures, waste-impacted
surface and groundwater, as well as drinking water.3-5 LC/MS/MS has successfully been
used to detect steroid hormones at low levels but the extraction efficiency and selectivity
for these compounds in current sample pretreatment methods limit the sensitivity of this
approach.6

Antibodies have been frequently used for the extraction and concentration of
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environmental contaminants. Previous work has used antibodies to create
immunosorbents to obtain low limits of detection for various target compounds in
analytical methods, as outlined in Chapters 1 and 2.6-9 Antibodies have many advantages
for this type of work, such as their high selectivity for a class of compounds, the
flexibility with which they can be developed for use with many analytes and types of
samples, and their ability to be functionalized with a variety of labels and reporting
agents to help achieve low limits of detection. However, the cost of antibodies is quite
high and their use in immunosorbents requires a step gradient to elute analytes. In
addition, there is the possibility that there will be interferences with immunosorbents
from compounds that are structurally similar to the analyte.
Serum transport proteins such as human serum albumin (HSA) and bovine serum
albumin (BSA) are possible alternatives to antibodies for use in the extraction of
emerging contaminants. These proteins bind many drugs and hormones with relatively
high affinity,10, 11 they are readily available, and they are much lower in cost than
antibodies. This chapter will examine the development of new affinity sorbents based on
BSA for the extraction and concentration of several compounds of environmental
concern from water samples.
Carbamazepine, estradiol, and estrone, were chosen as initial targets for this
study. Carbamazepine (Figure 5-1) is a widely used drug that is effective in treating
epilepsy as well as trigeminal neuralgia and bipolar depression12, 13 It is one of the most
commonly occurring pharmaceuticals in the environment and is found in municipal
sewage and surface water samples.14 Less than 10% of carbamazepine is removed during

sewage treatment and this drug has been detected at levels up to 1.075 µg/L in surface
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water, up to 1.1 µg/L in groundwater, and up to 0.030 µg/L in drinking water.14
Carbamazepine’s wide occurrence and relatively large concentrations in water samples
make it ideal for use as an anthropogenic marker for wastewater.13 In addition, it is one
of the few drugs for which the lowest observed effect concentration (LOEC) for chronic
toxicity to aquatic organisms is close to levels observed in wastewater effluents.1
The naturally-occurring female hormone 17β-estradiol and its oxidation product
estrone (Figure 5-1) have also been reported in sewage treatment plant effluents.2 These
steroid hormones are of concern because they disrupt the endocrine function of aquatic
organisms at environmentally relevant levels.2
The remaining compounds used in this study were chosen based on their wide
occurrence in natural and treated waters and their inclusion in the current lists of priority
emerging contaminants.15-18 These other targets are listed in Table 5-1, which also shows
the uses and properties of these agents. The structures of these other targets are provided
in Figure 5-1.
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Table 5-1. Compounds used in this study and their properties and uses.

Compound

Use

2,4-Dichlorophenoxyacetic acid

Herbicide

Atrazine

Herbicide

Caffeine

Central nervous system stimulant

Carbamazepine

Anticonvulsant

17β-Estradiol

Natural female hormone

Estrone

Oxidation product of 17β-estradiol

Ibuprofen

Anti-inflammatory agent with analgesic properties

Testosterone

Natural male hormone
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Figure 5-1. Structures used as model target analytes in this study.
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Because the ultimate goal of this research was to provide a means for the on-line
extraction and concentration of emerging contaminants prior to LC/MS/MS analysis, the
performance of a BSA column was tested in such an experimental set-up using
carbamazepine as the analyte. The system that was used for this type of study is
illustrated in Figure 5-2, with an enlarged view of the valve configuration also being
provided. In this system, the sample was applied to the BSA column in water, and eluted
and passed onto a reversed-phase liquid chromatography (RPLC)precolumn using a
mobile phase that was also suitable for use with the BSA (e.g., 2% 1-propanol in water
containing 0.5 g/L ammonium formate). The mobile phase passing through the RPLC
precolumn was then switched to 75% methanol/25% water and the sample was applied as
a narrow plug to a larger RPLC analytical column. Tandem mass spectrometry was used
for detection as compounds eluted from the analytical column.
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Figure 5-2a. Experimental set-up used for testing an affinity column containing BSA
on-line with detection based on tandem mass spectrometry.
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Figure 5-2b. An expanded view of the valves used in the chromatographic system for
affinity extraction coupled with tandem mass spectrometry.
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C18 RPLC columns or cartridges are usually used to extract and concentrate
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analytes from environmental samples. In order to compare the binding capacity of
columns containing BSA sorbents to those containing C18, frontal analysis experiments
were conducted as part of this study. In this type of experiment, a sample containing an
analyte of known concentration is continuously applied to the column until the binding
sites in the column are saturated. As this occurs, the amount of analyte being detected in
the eluent increases and a breakthrough curve is obtained. If several different
concentrations of the analyte are applied and the association/dissociation kinetics for
analyte binding are relatively fast, the binding capacity of the analyte on the column can
be calculated by using the following equation, which relates the time at which the center
of the breakthrough curve occurs to the concentration and moles of applied analyte.19
1
mLapp

=

1
1
+
K A mL [A] mL

(1)

In Equation 1, mLapp is the apparent moles of analyte required to saturate the column at a
given concentration of analyte, Ka is the association equilibrium constant for the binding
between the analyte and its ligand binding sites in the column, mL is the total binding
capacity of the ligand binding sites in the column, and [A] is the concentration of
analyte.19
In this study, to determine and compare the relative affinity of each type of
column that was used for the given target analytes, the retention times and retention
factors for each target on each column were determined. The samples were prepared and
injected into various buffers and solvents to compare various conditions for sample
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application and elution on such columns. A pH 7.4, 0.067 M potassium phosphate buffer
was used as the main reference application buffer because this buffer is commonly
employed with columns containing BSA or other proteins to study their binding under
physiological conditions. A 2% solution of 1-propanol in water was also tested as a
possible mobile phase for the BSA column. Low concentrations of polarity-reducing
agents such as 1-propanol or other alcohols are often used in elution buffers for
immunoaffinity columns because they reduce the hydrophobic forces between antigens
and antibodies.20 A mobile phase containing a 75% methanol/25% water mixture was
also tested because this solution is a typical mobile phase that could be used with a C18
column. Ammonium acetate buffer was included in this system design because this
buffer is compatible with mass spectrometric detection.
The retention factor (k’) for each eluting target was determined by using Equation
2, where tR is the retention time of the analyte and tM is the column void time, as
determined by measuring the retention time of a non-retained compound such as sodium
nitrate.21
k'=

tR − tM
tM

(2)

To compare the band-broadening for each peak of the injected targets, the plate height
(H) was calculated for each analyte on each column by using Equation 3,

H =L

σ t2
t R2

(3)

where σt2 is the variance of the analyte’s peak with respect to time, L is the length of the
column. and tR is the retention time of the analyte.21 To understand how retention of each
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analyte changed with different elution and column conditions, computer simulations were
carried out. These simulations were based on a countercurrent distribution model,22-25
with the results then being compared to the experimental results and to the results for
other target analytes.

EXPERIMENTAL
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Reagents
BSA was obtained from Sigma-Aldrich (St. Louis, MO) and had a purity of 98%.
HPLC-grade Nucleosil 300-5 silica (300 Å pore size, 5 µm diameter) was obtained from
Macherey-Nagel (Düren, Germany). Carbamazepine, β-estradiol, estrone, ibuprofen and
testosterone were obtained from Sigma-Aldrich. Atrazine and 2,4-D were obtained from
Riedel-de Haën/Sigma-Aldrich (Seelze, Germany). Caffeine was obtained from Alfa
Aesar (Ward Hill, MA). All other chemicals were of the purest grades available. All
solutions were prepared using water from a Nanopure purification system (Barnstead,
Dubuque, IA).
Apparatus
The chromatographic system used for the determination of binding capacity and
retention consisted of a LC-10AD solvent delivery system from Shimadzu (Kyoto,
Japan), a 515 HPLC pump from Waters (Milford, MA), a LabPro injection valve from
Rheodyne (Oak Harbor, WA), and a UV-2075 Plus Intelligent absorbance detector from
Jasco (Easton, MD). Data were collected using software and an interface from National
Instruments (Austin, TX). Data analysis was performed using Peak Fit (SeaSolve
Software) and Excel (Microsoft, Redmond, WA). The on-line extraction experiments
were performed on a ThermoFinnigan (San Jose, CA) LCQ ion trap liquid
chromatograph/mass spectrometer system (LC/MS/MS). Simulations were performed
using spreadsheet calculations prepared in Excel. All supports were downward-slurry
packed using an HPLC column packer from Alltech (Deerfield, IL). The C18 guard

cartridges (10 x 2.1 mm, 5 µm particle size) were obtained from Thermo Hypersil
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(Waltham, MA).
Column Preparation
The diol-bonded silica used for BSA immobilization was prepared from Nucleosil
300-5 silica according to a previous method.26 The BSA was immobilized to this silica
support by the reductive amination method.27
Chromatographic Conditions
Each BSA silica support was downward-slurry packed at 4000-4500 psi for 1 h
into separate 50 x 4.6 mm I.D. or 10 x 2.1 mm I.D. stainless steel columns. The packing
solution was pH 7.4, 0.067 M potassium phosphate buffer. Injected samples had a
volume of 5 µL. The flow rate used in all chromatographic experiments was 1 ml/min.
For the determination of retention, all samples had a concentration of 2 ppm and
were prepared in pH 7.4, 0.067 M potassium phosphate buffer, pH 7.4 0.010 M
ammonium acetate buffer, 2% 1-propanol in water or 75% methanol/25% water. The
detection wavelengths used in this study were 230 nm for carbamazepine, 225 nm for
estrone, 225 nm for estradiol, 249 nm for testosterone, 275 nm for caffeine, 220 nm for
ibuprofen, 223 nm for atrazine, 223 nm for 2,4-D and 205 nm for sodium nitrate. Each
sample was injected in triplicate and the average of the resulting peak parameters were
used for the calculation of retention factors or plate heights. All experiments were
performed at room temperature. For the determination of binding capacity, the
carbamazepine samples were prepared in water at concentrations of 1 x 10-5 M, 2 x 10-5
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M and 5 x 10-5 M. For the on-line extraction experiments, the carbamazepine samples
were prepared in water and had concentrations ranging from 10 ng/L to 10 µg/L.
Computer Model
Simulations were performed using spreadsheet calculations prepared in Excel and
a countercurrent distribution model. 22-25, 28, 29 The input parameters included the
analyte’s retention factor and plate height, sample volume and concentration, flow rate
and column size. An example of this type of spreadsheet is provided in the Appendix.
Further details on the simulation method are provided in the Results and Discussion.

RESULTS AND DISCUSSION
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Initial studies demonstrated that a 50 x 4.6 mm i.d. BSA column could be used to
successfully trap a 24 ng sample of carbamazepine from an injected 10 ng/L sample. The
carbamazepine was eluted in this case onto a RPLC precolumn using 2% 1-propanol as
the mobile phase. This precolumn was used to refocus the eluted carbamazepine and to
avoid later injecting phosphate buffer into the LC/MS/MS system. The retained
carbamazepine was then eluted from the RPLC precolumn and applied onto a longer
analytical RPLC column by using 75% methanol/25% water as the mobile phase. The
resulting mass spectrum that was obtained when using this approach is shown in Figure
5-3. The peaks seen at m/z values of 194 and 237 are characteristic of carbamazepine.
The corresponding chromatographic peak, as shown in Figure 5-4, gave an easy to detect
signal for carbamazepine but was approximately 8 min wide.
In an effort to obtain a narrower peak, smaller 10 x 2.1 mm i.d. BSA columns
were prepared. The binding capacity of this type of column was then estimated and
compared to that for a C18 precolumn with the same dimensions. The latter is commonly
used for the pretreatment of environmental samples. It was found in this comparison that
the C18 column had a binding capacity of approximately 1.0 x 10-8 mol for
carbamazepine, as determined by frontal analysis. The BSA column had only a slightly
lower binding capacity of 0.8 x 10-8 mol, which indicated that both types of supports
could be used to bind to roughly equivalent amounts of this drug in the presence of an
aqueous mobile phase.
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Figure 5-3. Mass spectrum obtained after on-line extraction of carbamazepine from
water using a BSA column in an LC/MS/MS experiment.
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Figure 5-4. Chromatogram obtained after on-line extraction of carbamazepine from
water using a BSA column in an LC/MS/MS experiment.
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Tables 5-2 and 5-3 list the average retention factors and plate heights that were
next measured on 10 x 2.1 mm i.d. columns containing BSA and C18 and using pH 7.4,
0.067 M potassium phosphate buffer as the mobile phase. For some of the compounds
that had low retention (e.g., caffeine), the plate heights were difficult to measure
accurately because of the effects of extra-column band-broadening at the short retention
times observed for such compounds. Carbamazepine was found to have a retention factor
of 1.0 on the BSA column in the presence of the pH 7.4, 0.067 M phosphate buffer,
which made this a useful reference point for comparison with the retention of the other
compounds, columns and mobile phases that were also examined in this study. Several
of the tested compounds (i.e., ibuprofen, testosterone, β-estradiol, estrone and 2,4-D) had
much greater retention factors than carbamazepine on the BSA column. Also, the
majority of the retention factors on the BSA column were significantly greater than the
corresponding retention factors for the same analytes on the C18 column. These results
indicated that BSA could have significant binding to a range of different compounds (i.e.,
drugs, steroid hormones, and pesticides). The greater affinity of this material for these
compounds of interest in the presence of an aqueous solvent makes this type of support
an attractive alternative to C18 for on-line extraction and the concentration of emerging
contaminants from water.
Excluding the compound with the lowest retention (i.e., for which the efficiencies
were artificially high due to extra-column effects), the plate heights measured for the
BSA column ranged from 0.02 to 0.35 cm, with an average of 0.13 cm. Because most of
the tested compounds had low retention on the C18 column under aqueous conditions, the
plate heights were difficult to measure accurately for all analytes except ibuprofen. The
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plate height for this drug was 0.4 cm on the C18 column while it was 0.02 cm on the BSA
column. This greater efficiency for the BSA column under aqueous conditions is another
potential advantage for this material as an alternative to C18 for sample extraction.
Table 5-4 lists the retention factors that were measured with other mobile phases
on the same two types of columns. In general, the retention factors decreased
significantly in going from a pH 7.4, 0.067 M potassium phosphate buffer to a mobile
phase that contained 2% 1-propanol on the BSA column. This difference would make
the latter mobile phase a good elution buffer when transferring the extracted analytes
from the BSA column to a RPLC column. In contrast, going from the pH 7.4, phosphate
buffer to a 75% methanol/25% water mobile phase on the C18 column resulted in a slight
increase in the retention factor. However, this was to be expected since this new mobile
phase is a typical RPLC solvent and the retention times with the phosphate buffer on the
C18 column were quite low, as can occur in the presence of a highly aqueous solution for
this type of support. These results confirmed that an aqueous buffer was a better mobile
phase for application to the BSA column than for the C18 column. This difference
indicated that a BSA column would be more suitable than a C18 column for use in
extracting emerging contaminants from water. An ammonium acetate buffer was also
tested for use on these columns because of its compatibility with mass spectrometric
detection.

While the retention factors on the BSA column were similar for some of the

compounds, they decreased drastically for β-estradiol, estrone and ibuprofen, making this
mobile phase a poor choice for a sample application buffer but a possible candidate as a
mild elution buffer for this column. In contrast, the ammonium acetate buffer gave
greater retention for some of the compounds on the C18 column.
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Table 5-2.

Retention factors measured for the model analytes on BSA and C18
column in the presence of pH 7.4, 0.067 M potassium phosphate buffer as
the mobile phase.

Retention factor, k’a

Analyte

a

BSA

C18

Caffeine

0.04

0.04

Atrazine

0.64

0.06

Carbamazepine

1.0

0.08

Testosterone

2.4

0.18

Estrone

11.0

0.09

Ibuprofen

11.0

0.62

2,4-D

12.0

0.13

β-Estradiol

19.8

0.07

These results are the averages for triplicate injections. The typical precision for these

measurements was ± 2-3%.
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Table 5-3.

Plate height values measured for the model analytes on BSA and C18
column in the presence of pH 7.4, 0.067 M potassium phosphate buffer as
the mobile phase.

Plate height, H (cm)a

Analyte

a

BSA

C18

Caffeine

>1.0

>1.0

Atrazine

0.35

>1.0

Carbamazepine

0.14

>1.0

Testosterone

0.21

>1.0

Estrone

0.02

>1.0

Ibuprofen

0.02

0.4

2,4-D

0.03

>1.0

β-Estradiol

0.13

>1.0

These results are the averages for triplicate injections. The typical precision for these

measurements was ± 7-11%%.
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Table 5-4. Retention factors measured for the model analytes on BSA and C18 column in
the presence of mobile phases containing 2% 1-propanol, 75% methanol/25%
water or pH 7.4, 0.010 M ammonium acetate buffer.

Retention factor, k’a

Analyte

a

BSA

C18

BSA

C18

2%

75% methanol/25%

pH 7.4, 0.010

pH 7.4, 0.010

1-propanol

water

M ammonium

M ammonium

acetate

acetate

Caffeine

1.18

0.17

0.10

0.22

Atrazine

0.32

0.29

0.50

8.32

Carbamazepine

0.63

0.23

0.95

14.2

Testosterone

1.03

0.42

1.75

-

Estrone

0.24

0.31

0.03

-

Ibuprofen

0.31

0.19

0.04

1.63

2,4-D

7.78

0.14

-

0.13

β-Estradiol

0.17

0.33

1.03

0.06

These results are the averages for triplicate injections. The typical precision for these

measurements was ± 3-5%.
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Computer modeling was next used to simulate the elution profiles for the target
analytes under various retention conditions. In this approach, the number of theoretical
plates for the column was represented by equal segments in an Excel spreadsheet. The
movement of an analyte through this column was simulated by using a countercurrent
distribution model.22-25, 28, 29 In this model, a given amount of analyte was applied to the
first segment of the column, allowed to distribute between the mobile and stationary
phases in that segment, and then moved to the next segment while additional analyte was
applied to the first segment. The process was repeated throughout the length of the
column. The amount of analyte eluting in the mobile phase from the last segment was
then recorded and plotted as a function of time to produce the simulated chromatogram.
A representative spreadsheet (e.g., as used in modeling the elution profile of 2,4-D) is
provided in the Appendix.
Examples of the actual chromatograms and simulated chromatograms that were
obtained for some of the target analytes in this study are provided in Figures 5-5 through
5-9 for representative compounds from each category of analyte (e.g., drugs, pesticides
and hormones). The simulated chromatograms gave good agreement with the
experimental chromatograms in each case. For each analyte, the retention factor, plate
height, flow rate and column dimensions were input in order to calculate the void
volume, void time and number of segments required. A response value was calculated
using an arbitrary relative response factor and the number of segments calculated.
Figure 5-10 compares the simulated chromatograms for the compounds in Figure
5-5 through 5-9. It was possible from these plots to determine the sample application
conditions that were needed to collect or elute each compound in the presence of pH 7.4

phosphate buffer. For instance, the compounds that were observed to have relatively
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mild retention on the BSA column (e.g., atrazine, carbamazepine, testosterone) did not
begin to exit this column until after 1.2-1.5 times the column void volume (or void time)
but were almost completely eluted after 7-8 column volumes (e.g., carbamazepine and
atrazine) or 10 column volumes (testosterone). 2,4-D had a higher amount of retention,
with its elution from the column beginning around 7 column volumes and nearing
completion after 20 column volumes. β-Estradiol had the highest retention, with elution
beginning at 7 column volumes and continuing up to 50 column volumes. From this
information and these types of plots it is thus possible to estimate the conditions that are
needed for effective capture for each of these analytes and to adjust the selectively of the
BSA column to provide information on some groups of compounds versus others with
different levels of retention.
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Figure 5-5. Experimental and simulated chromatograms for carbamazepine, using a
normalized value of time on the x-axis. The BSA column was used with a
mobile phase consisting of pH 7.4, 0.067 M potassium phosphate buffer.
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Figure 5-6. Experimental and simulated chromatograms for atrazine, using a normalized
value of time on the x-axis. The BSA column was used with a mobile phase
consisting of pH 7.4, 0.067 M potassium phosphate buffer.
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Figure 5-7. Experimental and simulated chromatograms for testosterone, using a
normalized value of time on the x-axis. The BSA column was used with a
mobile phase consisting of pH 7.4, 0.067 M potassium phosphate buffer.
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Figure 5-8. Experimental and simulated chromatograms for 2,4-D, using a normalized
value of time on the x-axis. The BSA column was used with a mobile phase
consisting of pH 7.4, 0.067 M potassium phosphate buffer.
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Figure 5-9. Experimental and simulated chromatograms for β-estradiol, using a
normalized value of time on the x-axis. The BSA column was used with a
mobile phase consisting of pH 7.4, 0.067 M potassium phosphate buffer.
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Figure 5-10. Comparison of the simulated response for the compounds in Figures 5-5
through 5-9, using a normalized value of time on the x-axis. The BSA
column was used with a mobile phase consisting of pH 7.4, 0.067 M
potassium phosphate buffer.
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A column containing immobilized BSA was successfully used for the on-line
extraction of carbamazepine from water in a LC/MS/MS experiment. Although BSA
columns were found to have a slightly lower binding capacity than C18 columns of the
same size, they also had greater affinity for the target compounds examined in this study.
One advantage of BSA is that it is a general ligand for such compounds and can be used
to trap and elute these agents under isocratic elution conditions. In comparison,
antibodies tend to be specific for one compound or a few structurally similar compounds.
In addition, antibodies typically require a step gradient to release the captured analytes.
BSA is also easy to obtain and is inexpensive (i.e., less than 1 cent per milligram,
compared to hundreds of dollars per milligram for many antibodies). BSA also offers the
ability to provide more selective and stronger retention than C18 supports for the
emerging contaminants that were tested in this study. In addition, BSA is more suitable
for the application of aqueous samples.
The binding and elution of the target compounds from the BSA columns were
successfully simulated by using an Excel spreadsheet and a countercurrent distribution
model. The same approach could be used to examine other emerging contaminants or
elution conditions by changing the retention factor (i.e., to represent a change in the
analyte, mobile or stationary phase) and the plate height (i.e., to represent a change in
efficiency). As indicated in this study, these simulations should be useful for the future
optimization of on-line extraction based on BSA or other binding agents for other
emerging contaminants or compounds of interest in environmental samples.
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THE USE OF CHROMATOGRAPHIC PEAK PROFILING FOR THE STUDY OF
DRUG-PROTEIN BINDING KINETICS

INTRODUCTION
Drugs in the human body are often bound to plasma proteins, such as human
serum albumin (HSA) and α1-acid glycoprotein (AGP). HSA is the most important
plasma binding protein for many drugs and endogenous substances.1 It has a molecular
weight of 66,500 g/mol and is made up of a single polypeptide chain that contains 585
amino acids.2 The concentration of HSA in plasma ranges between 30 and 50 g/l, or
roughly 500 to 750 µM.3, 4 HSA is able to bind compounds with widely varying
structures. Two of the most important binding sites on HSA are Sudlow sites I and II.2
Sudlow site I binds to drugs such as warfarin that contain a cationic center. Sudlow site
II tends to binds drugs with arylpropionic acid, fenamanate or benzodiazepine groups.
Binding at both sites involves mostly hydrophobic interactions, but ionic interactions or
dipole-dipole interactions can also be involved.1 AGP binds mostly to basic drugs4 and
appears to have one, high-affinity site that involves mainly hydrophobic binding forces.5
The concentration of AGP in plasma is only 1/50th that of HSA,3 but the levels of AGP
do rise significantly during many disease states.4
Drug-protein binding in blood has been widely studied for many years because it
frequently affects the transport, distribution, metabolism and excretion of pharmaceutical
agents.3 It is for this reason that drug-protein binding with serum proteins is a routine

part of drug development.6 In addition, a number of disease states, especially those
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involving the liver or kidneys, are known to cause changes in drug binding in blood, thus
affecting the distribution and elimination of many pharmaceutical agents.1
Equilibrium constants are commonly used as a measure of the binding strength for
drug-protein interactions. However, only when kinetics are taken into account can a
complete description of this binding be obtained.4 Examples of processes in which the
rates of association and dissociation between drugs and proteins are important include
hepatic clearance and passage of a drug across the blood-brain barrier.4 This chapter will
use the methods of high-performance affinity chromatography and peak profiling to
examine the interaction rates of various drugs with HSA and AGP.
The peak profiling method allows calculation of the dissociation rate constant, kd,
between an analyte and a ligand by measuring the plate heights on a column containing
the ligand when injections are made for the analyte and a non-retained species at various
flow rates.4, 7, 8 This approach was used in this chapter to study binding by the drugs
paroxetine and diazepam to HSA and binding by the drug propranolol to AGP. Figure 61 shows the structures of these drugs. Paroxetine is a selective serotonin reuptake
inhibitor (SSRI) that is used to treat major depression, obsessive-compulsive disorder,
panic disorder, generalized anxiety disorder, post-traumatic stress disorder and social
phobia in adults.9 Previous studies have demonstrated relatively strong binding of
paroxetine to HSA (e.g., previously giving a retention factor greater than 5.7 on an HSA
column).10 Diazepam is one of the most often used benzodiazepine drugs. This group of
drugs has sedative, hypnotic, anti-anxiety, muscle relaxant and antiepileptic properties
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Figure 6-1. Structures of the drugs examined in this study.
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and is among the most commonly prescribed families of medications.11, 12 Diazepam is
also known to bind fairly strongly to HSA. The association equilibrium constants that
have been reported in the literature for this interaction have ranged from 1.2 x 105 to 1.7
x 106 M-1.13-15 Propranolol is a non-selective beta-adrenoceptor blocking agent that is
used to treat hypertension, coronary heart disease, cardiac arrhythmias and heart failure.16
The association equilibrium constants for the binding of propranolol to AGP have been
reported to be in the range of 105-106 M-1.17-22 The binding of propranolol to HSA has
been reported to have an association equilibrium constant in the range of 103-104 M-1.23, 24
The binding of a small drug with serum proteins is important because the drugprotein complex is not able to diffuse across membranes because of its high molecular
weight; only the free, or non-complexed, form of the drug is able to cross membranes.25
For many drugs, this makes the free drug form the biologically-active fraction in the
circulation.26 However, there are some cases in which the interactions of the binding
proteins with components in the microcirculation (e.g., arterioles, venules and capillaries)
can cause dissociation of the drug from a serum protein and enable transport of the drug
into tissues.27, 28 For example, it has been suggested that a fraction of warfarin that is
bound to serum proteins is available for tissue extraction as a result of enhanced
dissociation of the drug-protein complex in the tissue microcirculation, as noted in a
study of brain and salivary gland extraction of this drug in rats.29 Enhanced dissociation
from albumin of valproic acid in the brain microcirculation has also been observed.30
These effects make information on the kinetics of drug interactions with serum proteins
of great potential interest in helping to determine the relative importance of these
processes for drugs such as paroxetine, diazepam and propranolol.
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THEORY
The binding of a drug (D) to a serum protein (P) to form a reversible complex
(DP) can be described by the following equation,31

ka
𝐷 + 𝑃 ⇌ 𝐷𝑃
kd

(1)

where ka and kd are the association and dissociation rate constants for the binding process,
respectively. The association equilibrium constant for this process, Ka, is related to these
rate constants through the following expression.31
𝐾𝑎 = 𝑘𝑎 /𝑘𝑑

(2)

In this study, the peak profiling method was used to determine the dissociation
rate constants for several drugs with serum proteins. In this method, an immobilized
binding agent such a serum protein is employed while injections of a drug and of a nonretained solute are made at one or more flow rates.4, 8 An example of such a study is
shown in Figure 6-2. The chromatographic profiles (i.e., the positions and widths of the
peaks) for the retained and non-retained compounds are then measured at each flow rate.
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Figure 6-2. Experimental set-up and procedure for a peak profiling experiment.8
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The retention time for a retained drug can be related to the association equilibrium

constant for the drug-protein interaction and the width of the peak can be related to the
rates of association and dissociation for this interaction. The data that is obtained for the
non-retained compound is used to account for peak broadening due to sources other than
drug-protein binding, such as mass transfer and diffusion of the drug within the mobile
phase.4
The peak profiling method is a result of the work that was initially done by
Giddings and Eyring in 1955, when they developed a statistical description of molecular
migration in chromatography. This description depicted chromatographic peaks as
probability distribution functions.32 This theory was further developed, made more
general and applied to affinity chromatography by Denizot and Delaage in 1975.33 Based
on this previous work, the dissociation rate constant for the interaction of an injected
analyte with an immobilized binding agent can be described by the following equation,4
2( E[to ]) 2 ( E[t R ] − E[t0 ])
kd = 2
σ R ( E[to ]) 2 − σ 0 2 ( E[t R ]) 2

(3)

in which E[to] and E[tR] are the mean retention times of the chromatographic peaks for
the analyte and for a non-retained compound, respectively, and σR2 and σ02 are the
corresponding peak variances (i.e., measures of peak width). In order for this equation to
be valid, all sources of band-broadening other than analyte interactions with the
stationary phase must be similar for the analyte and non-retained compound or negligible
compared to analyte-stationary phase interaction under the conditions of the experiment.
This requirement typically means that relatively high flow rates are used for such studies
to maximize the contribution of analyte-stationary phase interactions to band-broadening
versus other band-broadening processes.4, 8
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An affinity column, like other types of chromatographic columns, can be thought
of as being made up of a series of equally sized regions, or theoretical plates. Each
theoretical plate can be thought of as representing a single interaction between the analyte
and the stationary phase. The length of the column that is taken up by a single theoretical
plate is referred to as the “plate height” and is represented by the term H. The value of
the plate height is related to the column length L by the term N, the number of theoretical
plates, where H = L/N. The number of theoretical plates, in turn, can be related to the
square of the retention time for an analyte, 𝑡𝑅2 , and the variance of the analyte’s peak, 𝜎 2 ,
as given by the relationship N = 𝑡𝑅2 / 𝜎 2 .34, 35

As a small sample of an injected analyte travels through a column, there are

several processes that cause broadening of the analye’s peak and contribute to the total
observed plate height, Htotal. The contributions to Htotal can be represented by the
summation of several separate plate height terms, as shown in Equation 4.

𝐻𝑡𝑜𝑡𝑎𝑙 =

𝐿𝜎𝑅2
= 𝐻𝑚 + 𝐻𝐿 + 𝐻𝑠𝑚 + 𝐻𝑘
𝑡𝑅2

(4)

In this equation, Hm represents the plate height contribution due to mobile phase mass
transfer and eddy diffusion, HL represents the contribution due to longitudinal diffusion,
Hsm results from stagnant mobile phase mass transfer, and Hk is the contribution from
stationary phase mass transfer. Another term representing extra-column band
broadening, Hec, is sometimes included with these other terms but can be eliminated if a
correction is made for such effects by subtracting from Htotal the band broadening results
for the analyte that are measured when no column is present in the system.
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In the peak profiling method, a simplification in Equation 4 is made which

assumes that HL produces only a negligible contribution to Htotal; this assumption is valid
for most types of liquid chromatography. It is also assumed that Hm is constant at the
flow rates that are typically used during the peak profiling measurements. If these
assumptions hold, the following equation can be used to determine the rate constant k-1
that describes stagnant mobile phase mass transfer on a control column that has little or
no retention for the analyte (i.e., the retention factor, k, is equal to zero).34, 36

𝐻𝑠𝑚 =

2𝑢𝑉𝑃
𝑘−1 𝑉𝑀

𝑓𝑜𝑟 𝑘 = 0

(5)

In this equation, u is the linear velocity of the mobile phase (i.e., as measured by using a
non-retained molecule), VP is the pore volume of the stationary phase, VM is the column
void volume, and k is the retention factor. To use this relationship, sample injections are
made at various flow rates to obtain plate height values on a control support that contains
no immobilized binding agent or stationary phase. Alternatively, a non-retained
molecule can be injected onto a column that does contain a stationary phase. If linear
regression is performed on a plot of Htotal versus u, the slope of this plot can be used to
obtain a value for k-1 by also using the known values of VP and VM for the column and
support. The intercept of this plot, which may be a positive non-zero value, can be used
to estimate the value of Hm.34, 37, 38
It is also possible to estimate the plate height contribution due to stagnant mobile
phase mass transfer by making injections of the analyte onto the affinity column at
several flow rates and measuring Htotal along with k. In this approach, the value obtained
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for k-1 from the previous set of experiments conducted on a control column or with a nonretained solute is used in the following equation to estimated Hsm.

𝐻𝑠𝑚

𝑉
2𝑢𝑉𝑃 (1 + 𝑉𝑀 𝑘)2
𝑃
=
𝑘−1 𝑉𝑀 (1 + 𝑘)2

(6)

With this approach, estimates for Hsm can be made at each flow rate and subtracted from
Htotal to give Hk. The expression for Hk, as given by Equation 7, can then be used to
calculate kd, the dissociation rate constant for the analyte/ligand interaction.34, 37

𝐻𝑘 =

2𝑢𝑘
𝑘𝑑 (1 + 𝑘)2

(7)

If a plot is made of Hk versus uk/(1+k)2, Equation 7 indicated that kd can be determined
from the slope of this plot.34, 37 To use this relationship, the ligands being studied must
have weak-to-moderate binding so that the association and dissociation rates of the
analyte-ligand interaction are fast enough to allow multiple binding and dissociation steps
to take place as the analyte passes through the column. This generally means that the
analyte-ligand interaction will have an association equilibrium constant in the range of
106 M-1 or lower. Another important consideration in this type of experiment is that the
amount of analyte that is injected should be small enough to ensure that linear elution
conditions are present (i.e., the retention factor should not change with the concentration
of the injected analyte).36-39
Band broadening measurements have been used in the past to examine a few
types of analyte interactions with affinity columns. For instance, an early example of the
use of this method to study reaction rates was in studies that examined the interactions of
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sugars with the lectin concanavalin A (Con A).40 Rate constants for the interactions of
R/S-warfarin and D/L-tryptophan with HSA have also been measured at various
temperatures by using this method.37, 38 Such information, along with studies on the
effects on pH, ionic strength and solvent polarity on kinetics, has been further obtained
and used to optimize chiral separations for R/S-warfarin and D/L-tryptophan on HSA
columns.37, 38, 41 Other examples of the usefulness of such studies can be found in the
use of rate constants of drug-protein interactions to examine the pharmacokinetics of drug
binding to HSA8, 42, 43 and to develop new assays for measuring free drug or hormone
fractions in serum.44
One assumption that was made in Equation 7 is that the stagnant mobile phase
mass transfer is the same for the retained and the non-retained species or that the plate
height contribution due to stagnant mobile phase mass transfer is significantly smaller
than that due to stationary phase mass transfer. However, since the retention factor k
affects the plate height due to stagnant mobile phase mass transfer, different contributions
to this term can occur for retained and non-retained solutes. In order to examine such
effects, the difference in each plate height contribution may be plotted versus the term
u k/(1+k)2 to compare the relative contributions due to stagnant mobile phase mass
transfer (Equation 8), stationary phase mass transfer from analyte interactions with the
support (Equation 9) and stationary phase mass transfer from analyte interactions with an
immobilized protein or other ligand (Equation 10).43
2𝑢𝑘

(𝐻𝑅 − 𝐻𝑀 )𝑠𝑚 =
�
(1+𝑘)2

(1+3�2𝑘)
𝑘−1

�

(8)
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2𝑢𝑘

∝𝑛

(9)

2𝑢𝑘

∝

(10)

(𝐻𝑅 − 𝐻𝑀 )𝑘,𝑛 =
� �
(1+𝑘)2 𝑘
𝑑,𝑛

𝑝
(𝐻𝑅 − 𝐻𝑀 )𝑘,𝑃 =
� �
(1+𝑘)2 𝑘
𝑑,𝑃

In Equation 8, k-1 is given by the following equation,
𝑘−1 =

60𝛾𝐷
2
𝑑𝑝

(11)

where γ is the tortuosity factor, D is the diffusion coefficient for the retained and nonretained solutes, and dp is the particle diameter of the support (i.e., 7 µm in this study).43
Typical values34 for γ and D of 0.5 and 1 x 10-5 cm2/s, respectively, were used in this
study. In Equation 9, kd,n is the dissociation rate constant due to binding of the analyte to
the support and αn is given by Equation 12,
𝛼𝑛 =

�1−𝑓𝑝 �𝑘𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑘

(12)

where kcontrol is the retention factor for the analyte on the control column and fp is the
fraction of the support surface covered by immobilized ligand,26, 34, 45 as calculated based
on the surface area and packing density of the support, the protein content of the column,
and the area of the protein.43 In Equation 10, kd,P is the dissociation rate constant due to
binding of the analyte with the protein or immobilized ligand, and αp is given by
Equation 13.
𝛼𝑝 = 1 − 𝛼𝑛

(13)

Another situation of interest is when there is more than one site of interaction
(e.g., a specific interaction of the drug with the immobilized protein as well as a non-
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specific interaction of the drug with the support). In this case, Equation 7 can be written
as shown below.43
𝐻𝑅 − 𝐻𝑀 = 𝐻𝑘,𝑃 + 𝐻𝑘,𝑛
=𝑘

2𝑢𝑘𝑝

2
𝑑,𝑃 (1+𝑘)

2𝑢𝑘

+𝑘

∝𝑃

= (1+𝑘)2 �𝑘

𝑑,𝑃

2𝑢𝑘𝑛

2
𝑑,𝑛 (1+𝑘)

∝

+𝑘 𝑛�
𝑑,𝑛

(14)

EXPERIMENTAL

176

Reagents. The HSA (essentially fatty acid free, > 96%) and AGP (99 % pure)
were from Sigma-Aldrich (St. Louis, MO). The paroxetine (≥ 98%pure) and diazepam
were from Sigma-Aldrich. Racemic propranolol (99% pure) was from Aldrich
(Milwaukee, WI). The Nucleosil Si-300 (7 µm particle diameter, 300 Å pore size) was
from Macherey-Nagel (Duren, Germany). Reagents for the bicinchoninic acid (BCA)
protein assay were from Pierce (Rockford, IL). All other chemicals were of reagent
grade or better. All aqueous solutions were prepared with water obtained from a
Nanopure water system (Barnstead, Dubuque, IA).
Apparatus. The chromatographic system consisted of an LC-10AD solvent
delivery system from Shimadzu (Kyoto, Japan), a LabPro injection valve from Rheodyne
(Oak Harbor, WA) and a UV-2075 Plus Intelligent UV/Vis absorbance detector from
Jasco (Easton, MD). The sample loop had a volume of 5 µL. The column temperature
was maintained at 37.0oC by using a water jacket from Alltech (Deerfield, IL) and a
Fisher Scientific 9100 circulating bath (Westbury, NY). Data were collected using
LabView 5.0 software (National Instruments, Austin, TX) and an interface from National
Instruments (Austin, TX). Data analysis was performed using PeakFit 4.12 (Systat
Software, San Jose, CA), in which moment analysis was performed using an
exponentially-modified Gaussian fit (EMG) with a linear progressive baseline. The
residual option in PeakFit was used to determine the best fit for the chromatographic
peaks. All supports were downward-slurry packed using an HPLC column packer from
Alltech (Deerfield, IL).
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Column Preparation. The columns containing immobilized HSA or the control
support were prepared using Nucleosil Si-300 silica. The silica was first converted into a
diol form according to a previously reported method.46 The diol content of this material
was estimated to be 230 (± 20) µmol diol/g silica (± 1 S.D.), based on previous
determinations by an iodometric capillary electrophoresis assay.47 Part of the diol silica
was used to immobilize HSA by the Schiff base method41 and part was used to prepare a
control support in which no protein was added during the immobilization step. AGP was
immobilized to hydrazide-activated silica, following a previous method.17 The control
support for the AGP column was the hydrazide-activated silica with no protein
immobilized to it. The HSA support was found to have 40 (± 2) mg HSA/g silica, as
determined in triplicate by a BCA protein assay using HSA as the standard and the
control support as the blank. The supports were downward slurry-packed at 24-28 MPa
(3500-4000 psi) into 5 cm × 4.6 mm i.d. and 1.9 cm x 2.1 mm i.d. stainless steel columns
using pH 7.4, 0.067 M potassium phosphate buffer as the packing solution. The columns
were stored at 4oC in pH 7.4, 0.067 M phosphate buffer.
Chromatographic Studies. Experiments were performed at 37°C with a mobile
phase of pH 7.4, 0.067 mM potassium phosphate buffer in order to simulate physiological
conditions. All samples were also prepared in this buffer. The flow rate used ranged
from 0.5 to 4.0 ml/min and was increased in 0.5 ml/min increments. The detection
wavelengths were 205 nm, 209 nm and 225 nm for sodium nitrate, paroxetine and both
propranolol and diazepam, respectively. Sodium nitrate was used as the non-retained
species. Retention times were corrected by subtracting the time for analytes to elute from
a zero-volume connector. The injected samples contained 25 µM paroxetine; 100 µM
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diazepam; 25 or 100 µM propranolol; and 25 or 100 µM sodium nitrate (i.e., used as a
non-retained solute), as based on conditions identified previously as being suitable for
peak profiling.8 Injections for all analytes were typically made in triplicate. Similar
injections were made using a zero volume union to correct for the contributions to the
elution time or band-broadening by extra-column components of the system. The elution
times and variances for the eluting peaks (after correcting for extra-column effects) were
used to determine the retention factors and total plate heights for the analytes on the HSA
column, AGP column and control columns.

RESULTS AND DISCUSSION
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Peak Profiling on Control Column. The types of HSA and AGP supports used
in this study have been shown previously to be good models for drug-protein interactions
and to have low non-specific binding for many pharmaceutical agents.17, 48-53 However, it
was found that the tested drugs did have some non-specific binding to these supports.
The retention factors on the control column for the HSA support were 0.03 (± 0.02) and
4.95 (± 0.59) for paroxetine and diazepam, respectively, and made up roughly 0.18% and
7.0% of the total retention seen for the same drugs on the HSA columns. The retention
factor for propranolol on the control column for the AGP support was 44.6 (± 4.0) and
made up 55.1% of the total retention seen for the propranolol on the AGP columns.
The dissociation rates for these non-specific interactions were studied by first
carrying out peak profiling experiments for each drug on its corresponding control
column. These data were used to prepare plots of (HR - HM) vs. uk/(1+k)2 and analyzed
according to a single-site model by using Equation 7. In the case of diazepam and
propranolol, the dissociation rate for the binding of these drugs with the control support
was negligible compared to the dissociation rates that were later measured for these drugs
with immobilized serum proteins. In the case of paroxetine, the dissociation rate constant
from the support was estimated to be 0.7 (± 0.1) s-1, as determined from the plot shown in
Figure 6-3.

180

Figure 6-3.

Use of the multiple flow rate peak profiling method to estimate the
dissociation rate constant for non-specific binding of paroxetine to the
control support. The equation of the best-fit line is shown. The standard
error of the slope is 0.65.
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Effects of Stagnant Mobile Phase Mass Transfer on Control Column. As
stated earlier, Equation 7 assumes stagnant mobile phase mass transfer is approximately
the same for the retained solute and non-retained solute or that its plate height
contribution is small compared to that for stationary phase mass transfer. However, the
retention factor (k) can affect the plate height due to stagnant mobile phase mass transfer
and lead to differences in this term when comparing retained and non-retained solutes.
The importance of this effect was examined by using a series of calculations based on
chromatographic theory along with the known experimental conditions and estimated
values of kd,n and kcontrol for each drug on the control column, as described in the Theory.
These calculations were carried out for paroxetine but not for diazepam or propranolol,
given the negligible values of kd,n for these drugs on the control support.
Figure 6-4 shows a theoretical plot of (HR - HM) vs. u k/(1+k)2 for paroxetine on
the control column. These results confirmed that the overall change in (HR - HM) for this
system would have been only about 0.005 cm over the flow rate range that was examined
in this study, which was on the same order of magnitude as the precision of the
experimental measurements made on the HSA and AGP columns.
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Figure 6-4.

Predicted contributions from various band-broadening processes for
paroxetine on a control column.
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Peak Profiling on Protein Columns. The next set of experiments used peak
profiling to determine the dissociation rate constants for diazepam and paroxetine on an
HSA column. At 2.5 mL/min, the elution of diazepam occurred in less than 1.5 min (see
Figure 6-5), and the elution of paroxetine required less than 5 min. Plots of (HR - HM) vs.
u k/(1+k)2 gave an overall positive slope that could be used to estimate the kd values for
paroxetine interacting with HSA and propranolol with AGP (e.g., see example in Figure
6-6). However, the single flow rate method of peak profiling was used to examine the
interactions of diazepam interacting with HSA because of the strong binding, slow
dissociation, and small changes in plate height that were present in the latter case.
Table 6-1 summarizes the results that were obtained. The apparent dissociation
rate constant that was estimated for paroxetine on the HSA column, and without any
correction for non-specific binding to the support, was 3.96 (± 0.54) s-1 at pH 7.4 and 37
ºC. For propranolol on the AGP column, the dissociation rate constant was estimated to
be 0.45 (± 0.25) s-1. The interaction of diazepam with HSA was found to be 0.11 (± 0.06)
s-1, as based on Equation 3. When a correction was made for non-specific binding, the
corresponding values for these same rate constants were 3.95, 0.20 and 0.10 s-1,
respectively. During this process, it was found that it was not necessary to correct for the
protein coverage of the support, which had only a small or insignificant effect on the
amount of support surface that was available for non-specific binding. For instance, the
values of αP that were calculated by using the measured protein content of the supports
and a cross sectional areas for the given proteins were only 0.02 (± 0.01), 0.0006 (±
0.0004), and 0.13 (± 0.01) for diazepam, paroxetine and propranolol, respectively.5,28,54
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Figure 6-5.

Chromatograms for (a) diazepam and (b) paroxetine on an HSA column.
The broad peaks result from Hk making the main contribution to
broadening and mainly reflect dissociation, which is slow.
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Figure 6-6. Plot of (HR - HM) vs. u k/(1+k)2 obtained for paroxetine on an HSA column.
The error bars represent the standard deviation in (HR - HM) values, taken as
an average at each flow rate. The equation of the best-fit line is shown. The
standard error of the slope is 0.22.
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No previous studies have reported the dissociation rate constants for these
interactions, although a kd value for diazepam interacting with HSA was measured using
another method and found to be 0.44 (± 0.02).55 However, these results do agree with the
range of kd values that have been measured for other drugs and solutes with HSA, such as
warfarin37, 56 and L-tryptophan.4, 8, 38
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Table 6-1. Dissociation rate constants estimated by the peak profiling method.a

Drug-Protein

kd (s-1)

Without correction for non-specific binding
Paroxetine – HSA

3.96 (± 0.54)

Diazepam – HSA

0.11 (± 0.06)b

Propranolol- AGP

0.45 (± 0.25)

With correction for non-specific binding

a

Paroxetine – HSA

3.95 (± 0.54)

Diazepam – HSA

0.10 (± 0.06)b

Propranolol- AGP

0.20 (± 0.25)

The values in parentheses represent a range of ± 1 S.D.

b

The single flow rate method gave better results for this drug.

CONCLUSIONS
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The method of peak profiling was used with HPAC to examine the binding
kinetics of the drugs diazepam and paroxetine with HSA and propranolol with AGP. The
estimated dissociation rate constants for diazepam and paroxetine with HSA were 0.100.11 s-1 and 3.95-3.96 s-1, respectively, at pH 7.4 and 37 °C. The dissociation rate
constant measured for propranolol with AGP was 0.20-0.45 s-1 at pH 7.4 and 37 °C.
Although these drugs, with the possible exception of paroxetine, had relatively fast
dissociation during their non-specific interactions with the support, these interactions did
indirectly affect the peak profiling results obtained on HSA and AGP columns through
the contribution of non-specific binding to the overall retention of the drugs.

A

correction was made for these retention effects. The approach described in this report is
not limited to the particular drugs and supports that were used in this study.

An

advantage of this peak profiling approach is its use of chromatographic data that is
relatively simple to obtain (i.e., retention times and peak widths) and the ability to
acquire such data in a matter of minutes. These features should make this method
attractive for use in solute-protein binding studies and in the high-throughput
determination of dissociation rate constants for drug/protein interactions for biomedical
and pharmaceutical research.
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SUMMARY AND FUTURE WORK

SUMMARY
This dissertation presented research involving various applications of affinity
chromatography. A brief introduction to emerging contaminants and related research
needs was given in Chapter 1. Chapter 2 provided an overview of immunosorbent use for
extraction of pesticides and carbamazepine from samples combined with RPLC and mass
spectrometric detection.
Chapters 3 and 5 centered on the development of novel affinity extraction
sorbents for environmental contaminants. Chapter 3 dealt with the synthesis of MIPs for
this purpose and associated difficulties, while Chapter 5 examined the successful use of
BSA for affinity extraction of emerging contaminants form water.
The use of immobilized serum proteins, HSA and AGP, to study their interactions
with pharmaceutical agents was the focus of Chapters 4 and 6. Various methods of
immobilization of AGP to silica were employed and optimized for use of this support in
the chiral resolution of mepivacaine and propranolol. These experiments were described
in Chapter 4 and it was found that a method of mild oxidation of AGP, followed by
immobilization to hydrazide-activated silica worked best for this application. Chapter 6
presented the use of chromatographic peak profiling to determine dissociate rate constant
values for the interactions of paroxetine and diazepam with HSA and propranolol with
AGP. Results were similar to literature values obtained using other methods. Non-

specific binding of these drugs to the stationary phase was taken into account and
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corrections to the values were made as a result.

FUTURE WORK
In order to produce MIPs suitable for chromatographic applications, other
methods of synthesis can be employed. These include multi-step swelling
polymerization, suspension polymerization and precipitation polymerization. These
methods are known to produce spherical MIPs with uniform sizes.
Future experiments dealing with emerging contaminants include the use of
antibody extraction columns for estrone, β-estradiol and possibly other compounds in
water samples. BSA and antibody columns can also be tested with spiked wastewater
samples and compared to C18 extraction cartridges. Ultimately, these sorbents can be
tested in field sampling, along with the use of POCIS extraction membranes.
Chapter 6 presented the first known use of AGP in the chromatographic profiling
method. These types of experiments with AGP will be continued with other drugs and
the interactions of chiral compounds with this protein will be examined in the context of
peak profiling.

Flowrate (ml/min):
Col. length (cm):
Col. ID (mm):
No. Slices:
Detector Cell:
Slices for Sample Inj:

Adjust to
mol A/cycle:
Detector Cell
Normalize 7.52287E-12
Time/tM or
Cumulat Cumulat
Time(min) Vol (mL) Vol/VM Response Response Response Next A input (mol)
0
0
0 0.00E+00 0.00E+00 0.00E+00 7.52287E-12
0.000831 0.000831
0.03 0.00E+00 0.00E+00 0.00E+00 7.52287E-12
0.001663 0.001663
0.06 0.00E+00 0.00E+00 0.00E+00 7.52287E-12
0.002494 0.002494
0.09 0.00E+00 0.00E+00 0.00E+00
0
0.003325 0.003325
0.12 0.00E+00 0.00E+00 0.00E+00
0
0.004156 0.004156
0.15 0.00E+00 0.00E+00 0.00E+00
0
0.004988 0.004988
0.18 0.00E+00 0.00E+00 0.00E+00
0
0.005819 0.005819
0.21 0.00E+00 0.00E+00 0.00E+00
0
0.00665 0.00665
0.24 0.00E+00 0.00E+00 0.00E+00
0
0.007481 0.007481
0.27 0.00E+00 0.00E+00 0.00E+00
0
0.008313 0.008313
0.3 0.00E+00 0.00E+00 0.00E+00
0
0.009144 0.009144
0.33 0.00E+00 0.00E+00 0.00E+00
0
0.009975 0.009975
0.36 0.00E+00 0.00E+00 0.00E+00
0
0.010806 0.010806
0.39 0.00E+00 0.00E+00 0.00E+00
0
0.011638 0.011638
0.42 0.00E+00 0.00E+00 0.00E+00
0
0.012469 0.012469
0.45 0.00E+00 0.00E+00 0.00E+00
0
0.0133
0.0133
0.48 0.00E+00 0.00E+00 0.00E+00
0
0.014131 0.014131
0.51 0.00E+00 0.00E+00 0.00E+00
0
0.014963 0.014963
0.54 0.00E+00 0.00E+00 0.00E+00
0
0.015794 0.015794
0.57 0.00E+00 0.00E+00 0.00E+00
0
0.016625 0.016625
0.6 0.00E+00 0.00E+00 0.00E+00
0
0.017456 0.017456
0.63 0.00E+00 0.00E+00 0.00E+00
0
0.018288 0.018288
0.66 0.00E+00 0.00E+00 0.00E+00
0
0.019119 0.019119
0.69 0.00E+00 0.00E+00 0.00E+00
0
0.01995 0.01995
0.72 0.00E+00 0.00E+00 0.00E+00
0
0.020781 0.020781
0.75 0.00E+00 0.00E+00 0.00E+00
0

3.00E-02
5.00E-03
1.00E+12

H (cm):
Sample vol (mL):
Rel Response A:

tM/cycle (min):
0.000831

9.05E-06

1.20E+01

Input Column Parameters
k:
mL (mol):
Conc. A (M):

Linear Elution Model - Simulated column - Results in terms of analyte in mobile phase

1.00E+00
1.00E+00
2.10E+00
3.33E+01
3.43E+01
6.014989

Calculated parameters
VM (mL):
0.027709
tM (min):
0.027709
Ka:
Ka/VM (mol):
tR (min):
0.360211
Total A (mol):
4.53E-11

Column Slice No. - A in mobile phase
1
2
3
4
0
0
0
0
5.79E-13 0.00E+00 0.00E+00 0.00E+00
1.11E-12 4.45E-14 0.00E+00 0.00E+00
1.61E-12 1.27E-13 3.42E-15 0.00E+00
1.48E-12 2.40E-13 1.29E-14 2.63E-16
1.37E-12 3.36E-13 3.04E-14 1.24E-15
1.26E-12 4.15E-13 5.39E-14 3.48E-15
1.17E-12 4.81E-13 8.17E-14 7.36E-15
1.08E-12 5.33E-13 1.12E-13 1.31E-14
9.93E-13 5.75E-13 1.45E-13 2.07E-14
9.17E-13 6.07E-13 1.78E-13 3.03E-14
8.47E-13 6.31E-13 2.11E-13 4.16E-14
7.81E-13 6.48E-13 2.43E-13 5.46E-14
7.21E-13 6.58E-13 2.74E-13 6.92E-14
6.66E-13 6.63E-13 3.04E-13 8.49E-14
6.15E-13 6.63E-13 3.31E-13 1.02E-13
5.67E-13 6.59E-13 3.57E-13 1.19E-13
5.24E-13 6.52E-13 3.80E-13 1.38E-13
4.83E-13 6.42E-13 4.01E-13 1.56E-13
4.46E-13 6.30E-13 4.20E-13 1.75E-13
4.12E-13 6.16E-13 4.36E-13 1.94E-13
3.80E-13 6.00E-13 4.50E-13 2.13E-13
3.51E-13 5.83E-13 4.61E-13 2.31E-13
3.24E-13 5.65E-13 4.71E-13 2.49E-13
2.99E-13 5.47E-13 4.78E-13 2.66E-13
2.76E-13 5.28E-13 4.83E-13 2.82E-13

APPENDIX - Representative partial spreadsheet for 2,4-D simulation

5
0
0.00E+00
0.00E+00
0.00E+00
0.00E+00
2.03E-17
1.14E-16
3.73E-16
9.10E-16
1.85E-15
3.30E-15
5.37E-15
8.16E-15
1.17E-14
1.62E-14
2.14E-14
2.76E-14
3.47E-14
4.26E-14
5.14E-14
6.09E-14
7.11E-14
8.20E-14
9.35E-14
1.05E-13
1.18E-13

6
0
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
1.56E-18
1.02E-17
3.81E-17
1.05E-16
2.39E-16
4.74E-16
8.51E-16
1.41E-15
2.21E-15
3.28E-15
4.68E-15
6.44E-15
8.62E-15
1.12E-14
1.43E-14
1.79E-14
2.20E-14
2.66E-14
3.18E-14
3.74E-14

7
0
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
1.20E-19
8.95E-19
3.75E-18
1.16E-17
2.91E-17
6.33E-17
1.24E-16
2.23E-16
3.76E-16
5.99E-16
9.13E-16
1.34E-15
1.90E-15
2.62E-15
3.52E-15
4.62E-15
5.96E-15
7.55E-15
9.41E-15

mL/slice (mol):
tM/slice (min):
VM/slice (mL):
mol A/cycle (mol):

8
0
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
9.22E-21
7.73E-20
3.60E-19
1.22E-18
3.36E-18
7.97E-18
1.69E-17
3.28E-17
5.91E-17
1.01E-16
1.63E-16
2.54E-16
3.80E-16
5.52E-16
7.80E-16
1.08E-15
1.45E-15
1.92E-15

0.000831257
0.000831257
7.52287E-12

9
0
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
0.00E+00
7.09E-22
6.60E-21
3.38E-20
1.25E-19
3.74E-19
9.59E-19
2.18E-18
4.54E-18
8.74E-18
1.58E-17
2.71E-17
4.46E-17
7.04E-17
1.07E-16
1.59E-16
2.30E-16
3.24E-16
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